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Caspases are the main initiators and executors of apoptosis, cleaving more than 
two hundred different targets in apoptotic cells. The activation of caspases results in the 
activation of multiple pathways leading to apoptotic cell death. 
CAD (Caspase Activated DNAse) exists in a complex with its inhibitor, ICAD, 
in living cells. The cleavage of ICAD by caspase-3 causes the release of CAD from 
ICAD. Activated CAD causes internucleosomal (about 200 bp) and large-scale (about 
50-200 kb) DNA fragmentation. In addition, CAD is required for the completion of the 
final chromatin condensation stage, involving the formation of apoptotic bodies. 
To study the role of ICAD splice forms ICAD-S and ICAD-L in vivo I 
constructed DT40 cell lines in which the entire coding regions of ICAD or ICAD plus 
CAD had been deleted. ICAD' and ICAD-'-ICAD' double knockouts lacked both DNA 
fragmentation and nuclear fragmentation after the induction of apoptosis. I constructed a 
humanized system in which hICAD-L and hCAD expressed in DT40 ICAD-'-ICAD-1- 7 ' 
double le knockouts could rescue both DNA fragmentation and stage II chromatin 
condensation. hICAD-S could not replace hICAD-L as a chaperone for hCAD in these 
cells. However, caspase-resistant hICAD-S2T ', where the two caspase-3 cleavage sites 
were replaced for two TEV sites, did inhibit hCAD activation upon induction of 
apoptosis in vivo and in vitro. hICADL2TE'  was functional as a chaperone for hCAD, 
which was activated after hICADL2Tl  cleavage by TEV protease in vitro under non-
apoptotic conditions. Thus no other inhibitors of CAD exist in these cell-free extracts. 
Taken together, these observations indicate that ICAD-S may function together with 
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ICAD-L to prevent inappropriate CAD activation, particularly in cells where ICAD-S is 
the dominant form of ICAD protein. 
Because CAD is a nuclease, it is an attractive potential target for the induction of 
cell death. This could have a practical application as a strategy for killing cancer cells. 
The use of CAD as a drug target could be particularly advantageous since CAD is 
situated at the end of apoptotic pathway, and thus, once activated, CAD may avoid 
upstream regulatory mechanisms that protect cells against apoptotic stimuli involved in 
caspase-dependent apoptosis. I constructed a model system based on the ICAD/CAD 
double knockout to study the possibility that CAD can cause cell death. This system 
included hICAD12T':hCAD  and TEV protease under the control of an inducible 
promoter. However, it was not possible to cleave the hICADL2TE\f  protein in vivo with 
TEV protease, despite the fact that it was possible to do so in vitro. As an alternative 
strategy, I used PreScission protease, whose active part is 3C protease originating in 
human rhinovirus. A cleaved fragment of hICAD-121 protein was detected in DT40 
cells expressing PreScission protease. Preliminary data suggest that CAD contributes to 
cell death in cells expressing hICAD-L2 ':hCAD and transfected with PreScission 
protease. 
3 
2. General introduction 
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2.1 Different forms of cell death 
Cell death can occur accidentally, or it can be tightly regulated. The process of 
cell death can be encoded in programmes responsible for controlled execution of the cell 
a process known as programmed cell death. There are two main pathways in cells 
operating a programmed cell death mechanism: apoptosis and autophagy (Fig. 2.1). In 
contrast to programmed cell death, cells can sometimes die as a result of accidental 
physical or chemical damage, and this is termed necrosis. 
Cell death 
Programmed cell death 	 Accidental cell death 
\ 
L Apoptosis 	 Autophagy 	 Necrosis 
Fig. 2.1. The cell death pathways. Programmed cell death can be accomplished through 
apoptosis and autophagy mechanisms. 
2.1.1 Apoptosis 
Apoptosis, a term originating in the Greek word describing leaves falling off a 
tree (Kerr et al., 1972), is a form of programmed cell death leading to the elimination of 
useless, damaged or harmful cells in metazoans. It is required to eliminate unnecessary 
cells during the organism's development and adult life. Apoptosis is used during 
development to eliminate cells of the immune system that react with the organism's own 
antigens (Jacobson et al., 1997; Krammer, 2000). Apoptosis is also activated in cells that 
have suffered too much damage to continue their function. In addition, cytotoxic T-
lymphocytes can induce apoptosis in cancer cells and in virus-infected cells to help 
eliminate cells that may cause harm to the whole organism. Defects in the apoptotic 
process can be the cause of cancer, autoimmune and neurodegenerative diseases 
(Thompson, 1995). 
The components of the apoptosis pathway were first identified in the nematode 
Caenorhabditis elegans, where genetic studies revealed the existence of genes required 
for programmed cell death (Ellis and Horvitz, 1986; Yuan et al., 1993). The genes 
involved in apoptosis were then identified in mammals and in a wide range of 
multicellular organisms, including humans (Vaux and Korsmeyer, 1999). 
The process of apoptosis can be achieved by the activation of extrinsic & 
intrinsic pathways that regulate and accomplish the cell death. Apoptosis is defined by 
characteristic morphological and biochemical features. Morphological features include 
separation from neighbouring cells, cell shrinkage, loss of microvilli, membrane 
blebbing, chromatin condensation and formation of apoptotic bodies (Hacker, 2000; 
Kerr, 1971; Kerr et al., 1972; Wyllie et al., 1980). Inflammation, however, is absent 
during apoptosis due to the anti-inflammatory interaction between apoptotic cells and 
macrophages (Gregory and Devitt, 2004). 
In addition, distinct biochemical changes occur in cells undergoing apoptosis. A 
family of cysteine-containing, 	artate-specific proteinases called caspases is a key 
component of the programmed cell death pathway (Earnshaw et al., 1999; Nicholson 
and Thornberry, 1997). Activation of the caspase cascade results in the cleavage of 
multiple caspase substrates. Caspases directly or indirectly cleave more than two 
hundred intercellular targets (Degterev et al., 2003; Earnshaw et al., 1999), which results 
in the degradation of cell components responsible for the maintenance and regulation of 
homeostasis. Protein degradation, loss of plasma membrane asymmetry, the 
mitochondrial transmembrane potential dissipation and accumulation of reactive oxygen 
species plus large-scale and oligonucleosomal DNA fragmentation, are the characteristic 
biochemical features of apoptosis (Grimsley and Ravichandran, 2003; Hacker, 2000; 
Wyllie, 1980; Ziegler and Groscurth, 2004). Interestingly, apoptosis can occur without 
caspases (Lorenzo and Susin, 2004), and caspases can work without apoptosis (Zeuner 
et al., 1999). 
2.1.2 Autophagy 
Autophagy is a process of destruction of cellular organelles and parts of 
cytoplasm in specialized vesicles using the cellular lysosomal system. The destruction of 
cell organelles can either be a process of organised cellular components turnover, or it 
can lead to cell death (Levine and Yuan, 2005). Autophagy is characterised by the 
formation of autophagosomes, large cytoplasmic vesicles bounded by a double 
membrane (Klionsky and Emr, 2000) that cause the destruction of engulfed cellular 
components once fused with lysosomes. The process is regulated by multiple molecular 
mechanisms (Eskelinen, 2005). The destruction allows for the release of the molecules 
for macromolecular synthesis or for their further processing as an energy source. If the 
cell is starved for structural components or energy, autophagy can be a survival strategy, 
as cells with mutations in autophagy-linked genes die early under starvation conditions 
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(Tsukada and Ohsumi, 1993). Autophagy can also allow for the elimination of damaged 
organelles or of organelles not required for further cell development (Levine and 
Klionsky, 2004; Rusten et al., 2004). 
In addition to the biochemical features, morphological characteristics of 
autophagic cell death include multiple vacuolisation and chromatin condensation. In the 
end, the cells are engulfed by macrophages, and no inflammation develops (Bursch, 
2001; Clarke, 1990). 
2.1.3 Necrosis 
By contrast to the programmed cell death mechanisms described above, necrosis 
is an accidental event of cellular damage by physical or chemical factors. Necrosis is 
characterised by the rupture of cell and organelle membranes, mitochondrial swelling 
and disintegration of the nucleus, sometimes with initial chromatin condensation. Unlike 
programmed cell death, necrosis leads to an inflammatory response. (Wyllie et al., 1980; 
Ziegler. and Groscurth, 2004). Interestingly, even if necrotic cell death is accidental, 
under specialised circumstances, some molecular mechanisms shared with the 
programmed cell death pathways can be involved in necrosis once it is initiated (Festjens 
et al., 2006). 
2.2 Cellular pathways of apoptosis 
Apoptosis can be activated in cells in response to outside stimuli through the 
death receptor pathway, or, alternatively, it can be initiated as a result of intrinsic 
cellular signals through the mitochondrial pathway (Hengartner, 2000). Modulation 
[4] 
exists between both pathways to ensure that the cell death activation mechanism is under 
tight control. 
2.2.1 Death Receptor pathway of caspase activation 
The death receptor pathway can activate apoptosis in response to extracellular 
ligands (Ashkenazi and Dixit, 1998). Peath receptors (DR) belong to the Tumour 
Necrosis Factor (TNF) superfamily (Smith et al., 1994), which has eight members 
(Lavrik et al., 2005). They are situated in the cell membrane and have extracellular and 
cytoplasmic domains (Smith et al., 1994); appropriately, a portion of the cytoplasmic 
domain is also termed the "death domain" (Tartaglia et al., 1993). The two most 
extensively characterized receptors are Fas/CD95 (DR2) and Tumour Necrosis Factor 
Receptor I TNFRI/DR1 (Ashkenazi and Dixit, 1998; Krammer, 2000) (Nagata, 1997); 
their ligands are FasL and TNF, respectively. Other death receptors include: DR3, 
TRAILR1 (DR4), TRAILR2 (DR5), DR6, EDAR and NGFR (Lavrik et al., 2005). 
Fas receptor signalling 
FasL/CD95 is a protein, which was initially identified to be expressed on the 
surface of cytotoxic T-lymphocytes after their activation to initiate the killing of target 
cells (Li et al., 1998b). Upon FasL binding, Fas receptor forms stable trimeric aggregates 
(Fig. 2.2). This results in the aggregation of its cytoplasmic death domains (DD), which 
in turn bind to the death domains of the Fas-associated Death Domain (FADD) protein 
(Boldin et al., 1995; Chinnaiyan et al., 1995; Kischkel et al., 1995), triggering the 
formation of theDeath-Inducing Signalling complex (DISC) (Medema et al., 1997). 
FADD, in addition to having a death domain, also has death effector domains (DED). 
During the DISC complex formation, FADD's DED unmasks and recruits the DED of 
procaspase-8IFLICE (EADD-like  nter1eukin-1 converting enzyme) (Medema et al., 
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Fig. 2.2. Death receptor pathway of apoptosis activation in mammalian cells. Activation of death 
receptors Fas or TNF-R1 occurs through trimerization by their ligands, FasL or TNF, 
respectively. This results in the formation of the DISC complex, which consists of death receptor, 
FADD, procaspase 8 or adaptor molecule TRADD. The involvement of procaspase-10 is 
debatable. The dimer of procaspase-8 or procaspase-10 cleaves and activates itself in the DISC 
complex. Caspase-8 or caspase-10 then cleaves procaspase-3 leading to its activation. tBid 
transfers apoptotic signals from the cell surface to the mitochondria. In addition to their apoptotic 
function, death receptors can modulate survival pathways and genes. 
In the DISC, procaspase-8 molecules are grouped together. The key element of 
procaspase-8 activation is a dimer formation in the DISC complex (Boatright et al., 
2003; Chen et al., 2002), which results in the cross-cleavage of procaspase-8 molecules 
(Chang et al., 2003). Once a small amount of procaspase-8 is cleaved, the activated 
caspase-8 amplifies the signal by cleaving the rest of the procaspase-8 molecules (Muzio 
et al., 1998; Salvesen and Dixit, 1999). Activation of caspase-8 causes the cleavage of 
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procaspase-3 and other downstream targets, thereby amplifying pathways leading to 
apoptotic cell death. In addition to caspase-8, caspase-lO has been also proposed to have 
a role in initiating cell death receptor pathways. Caspase-10 is homologous to caspase-8 
and can be activated in a DISC complex (Kischkel et al., 2001; Wang et al., 2001). 
While caspase-lO can initiate apoptosis in the absence of caspase-8 (Milhas et al., 2005), 
the extent of caspase-10 activation in the absence of caspase-8 and its functional role 
remains controversial (Sprick et al., 2002). 
In addition to its apoptotic function, CD95IFas can also modulate survival 
signals (Lavrik et al., 2007). Expression of CD95 and CD95L was found during brain 
development (Park et al., 1998; Shin et al., 2002). Fas signalling can activate the 
extracellular-signal regulated kinase ERKIp35 pathway and promote branching of 
growing neurons (Desbarats et al., 2003; Zuliani et al., 2006). The modulation of 
survival signals can be also operated through c-FLIPs proteins, as described below. 
TNFR signalling 
TNFRI, following binding by its ligand TNF, operates in a way similar to 
Fas/FasL through trimerization to activate caspase-8, or alternatively, the NF-KB 
signalling cascade. TRADD (TNF-associated DeathDomain) is an adaptor molecule 
used in the TNFRI pathway (Hsu et al., 1995); it associates with the death domains of 
TNFRI upon its activation, and also with FADD, TRAF2 (TNFR-associated Factor 2) 
(Hsu et al., 1996b) and RIP (Receptor  interacting protein) (Hsu et al., 1996b; Ting et al., 
1996). TRADD facilitates the binding of FADD to form the DISC complex and 
activation of the caspase cascade. Alternatively, it can also bind TRAF2, which, together 
with RIP, activates the NF-KB signalling cascade and promotes cell survival (Hsu et al., 
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1996b) (Hsu et al., 1996a). The NF-KB pathway induces proinflammatory and 
immunomodulatory genes following TNF stimulation (Tartaglia and Goeddel, 1992), 
and regulates the expression of molecules involved in the immune response, immune 
cell development and apoptosis (Ghosh and Karin, 2002; Karin and Lin, 2002). The RIP 
family of kinases can also activate MAP (Mitogen-activated protein) kinases (Meylan 
and Tschopp, 2005), which are involved in the regulation of gene expression in response 
to extracellular stimuli (Turjanski et al., 2007). 
Inhibiting death receptor activation 
c-FLIPs (cellular FLICE inhibitory proteins) can inhibit the activation of 
apoptosis at the DISC complex (Krueger et al., 2001; Tschopp et al., 1998). Three c-
FLIP splice forms have been identified: c-FLIPs, C-FLIPL and c-FLIPR (Golks et al., 2005; 
Irmier et al., 1997). These proteins have two DED domains and structurally resemble 
procaspase-8. Their DED domains allow c-FLIPs to interact with the DED domains of 
FADD and procaspase-8 and disrupt their association, thus preventing apoptosis 
(Tschopp et al., 1998). c-FLIPs can inhibit a wide range of death receptor signalling 
receptors, including Fas and TNFR1 (Irmier et al., 1997). Interestingly, c-FLIPs have 
viral counterparts, v-FLIPs, which interact with FADD to prevent procaspase-8 
activation. They work to inhibit apoptosis during viral infection, thus providing viruses 
an opportunity to escape the host's defence mechanisms (Thome et al., 1997). Finally, 
beyond their anti-apoptotic function, c-FLIPs can stimulate the activation of the NF-KB 
signalling cascade (Golks et al., 2006; Hu et al., 2000), thus providing one more 
mechanism for cells to use external stimuli either to induce cell death or to modulate 
their development. In addition, activation of the NF-KB signalling pathway results in the 
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expression of more c-FLIP, thus providing a greater anti-apoptotic effect (Kreuz et al., 
2001). 
Transferring of apoptotic signals from the cell surface to the mitochondria 
The death receptor pathway can induce apoptosis in cooperation with the 
mitochondria through the action of caspase-8 and tBID (truncated BH3 Interacting 
Domain Death agonist) (Li et al., 1998a; Wang et al., 1996). This shunt can be initiated 
by small amounts of caspase-8 becoming active during membrane receptor stimulation. 
After its activation by FADD, caspase-8 can cleave BID, causing the formation of tBID. 
BID has a cytoplasmic localization, but after cleavage, tBID is associated with 
mitochondria (Gross et al., 1999b; Li et al., 1998a). As a result, the mitochondrial 
pathway of apoptosis is activated, leading to the release of cytochrome c. This pathway 
can be utilised if the stimulation of death receptors is insufficient for the direct activation 
of the caspase cascade (Scaffidi et al., 1998; Scaffidi et al., 1999). 
2.2.2 Mitochondrial pathway of caspase activation 
Internal and external stimuli converge on the mitochondria, causing the 
activation of caspase-dependent or caspase-independent apoptotic cell death pathways. 
These are thought to operate through apoptogenic factors released from the mitochondria 
to the cytoplasm, a process controlled by pro-apoptotic and anti-apoptotic proteins (Fig. 
2.3). 
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Fig. 2.3. Mitochondrial pathway of cell death. Multiple stimuli, including DNA damage and 
signals from the outer surface, can activate the mitochondrial pathway of cell death. This 
activation is modulated by pro-apoptotic and anti-apoptotic proteins. These have been proposed 
to control mitochondrial pathway activation through the formation of a pore complex containing 
Bax and Bak, which are required for the release of apoptogenic factors from the mitochondria. 
Alternatively, apoptogenic factors can be released through the PTP (permeability transition 
pore). Cytochrome c resides in the intra-cristae compartment, where its release is controlled by 
the cleavage of Opal. Once released from the cristae and the mitochondrial outer membrane, 
cytochrome c initiates the formation of apoptosome consisting of seven Apaf-1 and 
procaspase-9 molecules. Activation of caspase-9 occurs in apoptosome. Active caspase-9 then 
cleaves and activates procaspase-3. XIAP can prevent the activation of caspases, and 
therefore, either Smac or Omni is required to eliminate XIAP function. Caspase-independent 
apoptosis can occur without caspases through the release of AIF and endonuclease G from the 
mitochondria and their subsequent translocation to the nucleus. 
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The key component of caspase-dependent apoptosis, which involves the 
activation of the caspase cascade, is the release of cytochrome c from mitochondria. To 
leave the mitochondria, cytochrome c needs to get through the outer mitochondrial 
membrane, a process regulated by pro-apoptotic and anti-apoptotic proteins. 
Mitochondria also control caspase-independent apoptosis through the release of 
Apoptosis Inducing factor (AIF) and other factors. 
Mitochondria possess Bcl-2 family proteins that can modulate the release of 
apoptogenic factors through the outer mitochondrial membrane, and thus the initiation of 
apoptosis. They share a different number of conserved motifs termed BH (cl2 
homology) domains, and according to this and to their functions, are classified as pro-
apoptotic, anti-apoptotic and BH3 only pro-apoptotic proteins (Adams and Cory, 1998; 
Letai et al., 2002). 
Pro -apoptotic proteins 
Pro-apoptotic proteins have three BH domains (1-3). Pro-apoptotic proteins Bax 
and Bak could cause the release of apoptogenic factors by forming a pore complex in the 
outer mitochondrial membrane (Wei et al., 2001). To form a pore complex, Bax is 
transported from cytosol into the mitochondrial outer membrane (Wolter et al., 1997). 
The hypothesis of pore formation is still controversial, however, as it has also been 
suggested that Bax can modulate outer mitochondrial membrane permeability by 
destabilising lipid bilayers (Basanez et al., 2002) (Lucken-Ardjomande and Martinou, 
2005; Zamzami and Kroemer, 2003). 
Interestingly, in the Bax/Bak double knockout, it was still possible to induce 
apoptosis after certain apoptotic stimuli (De Marchi et al., 2004; Scorrano et al., 2003). 
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In this case, mitochondrial membrane permeability appears to be regulated via the 
permeability transition pore (PTP). Ca2 modulates the PTP opening in response to 
apoptotic stimuli (Crompton, 1999; Szalai et al., 1999). 
Anti-apoptotic proteins 
Anti-apoptotic proteins have four BH domains (1-4). The most well characterised 
anti-apoptotic proteins are Bcl-2 and Bcl-XL (Gross et al., 1999a; Yang et al., 1997). 
Anti-apoptotic proteins can prevent the release of cytochrome c and the initiation of 
apoptosis, possibly by preventing the formation of the Bax and Bak pore complex (Yi et 
al., 2003). The exact nature of how anti-apoptotic proteins prevent the release of 
cytochrome c remains unclear, but one possible mechanism may involve the 
sequestering of pro-apoptotic proteins and other components required for the formation 
of the pore complex (Cheng et al., 2001; Yi et al., 2003). 
BH3 -only pro-apoptotic proteins 
131-13-only pro-apoptotic proteins share a homology in the BH3 domain. One of 
the proteins from this family is tBid, discussed in the previous section. Transferring 
tBID to the mitochondria causes the release of cytochrome c by inducing 
oligomerization of the pro-apoptotic proteins Bax and Bak through direct interactions 
(Gross et al., 1999b; Korsmeyer et al., 2000; Li et al., 1998a). 131-13-only proteins can 
also interact and neutralise the action of anti-apoptotic proteins (Letai et al., 2002). 
One more step in the regulation of cytochrome c release from the mitochondria 
To leave the mitochondria, cytochrome c needs to get through the outer 
mitochondrial membrane, which is regulated by pro-apoptotic and anti-apoptotic 
proteins. According to recent studies, however, before it can accomplish this, it first 
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needs to leave the intra-cristae compartment where it is localised (Cipolat et al., 2006; 
Frezza et al., 2006). 
Opal (Qptic Atrophy fl is a protein that controls the release of cytochrome c 
from the intra-cristae compartment into the mitochondrial intermembrane space (Frezza 
et al., 2006). PARL (Presenilin-associated rhomboid-like)  is a protease that can either 
directly or indirectly cause Opal cleavage to produce a soluble form (Cipolat et al., 
2006). The cleavage of Opal results in channel remodelling and cytochrome c release 
into the intermembrane space. Interestingly, the tBid protein can induce cytochrome c 
release from intra-cristae compartments (Scorrano et al., 2002), possibly through action 
on Opal (Frezza et al., 2006). 
Stimuli converging on the mitochondria and inducing apoptosis 
DNA damage, cellular stress and oncogene expression can promote apoptosis 
through p53 activation. Phosphorylation activates p53 by increasing its stability, which 
then leads to either the arrest of the cell cycle or apoptotic cell death (Rich et al., 2000; 
Schuler and Green, 2001). p53  can induce apoptosis by activating the transcription of the 
mitochondrial pro-apoptotic proteins Bax, Noxa and Puma (Schuler and Green, 2001) 
and preventing the transcription of anti-apoptotic proteins (Wu et al., 2001), or by 
activating Bax through ASC (apoptosis-associated peck-like protein) (Ohtsuka et al., 
2004). p53 can also antagonise the action of mitochondrial anti-apoptotic proteins, such 
as such as Bcl-2 and Bcl-XL (Mihara et al., 2003). 
Proteins released from the mitochondria 
The main proteins released from the mitochondria during caspase-dependent apoptosis 
are cytochrome c, lAP, Smac/DIABLO and OmiIHtrA2. The factors released in caspase- 
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independent apoptosis are AIF and endonuclease G (Saelens et al., 2004), which are 
discussed in a later section. 
Cytochrome c 
Once released, cytochrome c initiates Apaf I (Apoptotic protease activating 
factor 1) (Zou et al., 1997) and procaspase-9 assembly in a complex that causes 
caspase-9 activation in the presence of ATP (Li et al., 1997). This complex is called the 
apoptosome (Cain et al., 2000). Seven Apaf-1 molecules oligomerize into a complex that 
recruits seven procaspase-9 molecules (Acehan et al., 2002). Activated caspase-9 then 
causes the cleavage of procaspase-3. 
lAPs, Smac/DIABLO and Omi/HtrA2 
lAPs (inhibitor of apoptosis proteins) can bind procaspase-9 and block its 
activation, as well inhibiting active caspase-9 and caspase-3 (Deveraux et al., 1998). 
Smac/DIABLO (Second mitochondria-derived activator of caspase1irect lAP binding 
protein with low p1) has been found to inactivate lAPs (Du et al., 2000; Verhagen et al., 
2000). Smac/DIABLO is localized in the mitochondria and released into the cytosol 
during apoptosis activation. However, apoptosis proceeds normally in Smac knockout 
mice (Okada et al., 2002). It is therefore possible that an alternative pathway exists for 
inactivating lAPs. This could operate through Omni/HtrA2, which, like Smac, is 
released from the mitochondria during apoptosis and is able to inhibit lAPs (Martins, 
2002; Martins et al., 2002; Suzuki et al., 2001). 
2.2.4 Caspase cascade 
Caspases exist in healthy cells in an inactive (zymogen) procaspase. Once 
activated by upstream regulatory pathways, they form the key element of a signal 
transduction cascade during apoptosis (Thornberry and Lazebnik, 1998). 
In general, 13 caspases have been identified in mammalian cells (Zhang et al., 
2003b; Koenig et al., 2001). Human caspase-4 and -5 do not have counterparts in mice, 
while mouse caspase-1 I and -12 do not have counterparts in human (Lamkanfi et al., 
2002). To activate procaspases, at least two cleavages must occur to separate the 
prodomain, large and small subunits (Earnshaw et al., 1999). After their cleavage, 
caspases form heterotetramers consisting of two large and two small subunits (Wilson et 
al., 1994). Based on their structure, regulation and targets, caspases can be divided into 
initiator and effector caspases. In addition, some caspases can perform additional 
specialised functions. 
Initiator caspases 
Initiator caspases work at the beginning of the caspase cascade. They contain 
long prodomains that take part in interactions with upstream regulatory molecules that 
activate the caspase cascade (Eamshaw et al., 1999). Caspase-2, -8, -9, -10 and -12 are 
initiator caspases involved in apoptosis (Degterev et al., 2003). As discussed in previous 
sections, caspase-8, -9 and possibly -10 are thought to be the key regulators of the 
caspase signal transduction cascade. 
Caspase-2 can initiate the mitochondrial pathway of apoptosis (Guo et al., 2002; 
Lassus et al., 2002). One of the possible mechanisms to achieve this is through the 
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cleavage of tBid. Caspase-2 can be activated as a result of heat-shock induced apoptosis 
(Tu et al., 2006). Once initiator caspases are activated, they cleave other initiator and 
effector caspases and amplify a positive feedback loop (Degterev et al., 2003). 
Effector caspases 
Effector caspases work downstream in the caspase cascade, and are processed by 
initiator caspases or by other effector caspases to amplify the apoptotic signal. Effector 
caspases include caspase-3, -6 and -7, all of which have short prodomains (Degterev et 
al., 2003; Earnshaw et al., 1999). The activation of effector caspases causes the cleavage 
of more than two hundred different cellular targets, which results in cell death. Caspase 
targets include apoptotic, cell cycle and inflammatory regulators, protein kinases, 
proteins involved in cell adhesion, nuclear membrane and cytoskeletal structural 
proteins, DNA synthesis and repair proteins, and proteins involved in transcription and 
translation (Fischer et al., 2003). 
Other caspases 
In addition to their role in apoptosis, some initiator caspases participate in the 
regulation of cytokine processing and inflammation processes. Caspase-1 is activated by 
caspase-5 in humans, or by the homologous caspase-1 1 in mice, in the intracellular 
complex termed the inflammasome (Degterev et al., 2003; Martinon and Tschopp, 
2004). Caspase-1 takes part in the production of interleukin-lp and interleukin-18, 
which are the major mediators of inflammation (Creagh et al., 2003; Martinon and 
Tschopp, 2004). 
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Another caspase with a specialised function is caspase-14, which can be 
expressed in epithelial cells (Pistritto et al., 2002). It is known to be involved in the 
differentiation of keratinocytes (Fischer et al., 2005), but the exact role of caspase-14 
requires further clarification. 
2.2.4 Caspase-independent cell death 
Apoptotic stimuli acting on mitochondria can initiate cell death without the 
activation of caspases (Susin et al., 2000; Susin et al., 1999). AIF has been proposed to 
be a major factor contributing to caspase-independent cell death (Cande et al., 2002; 
Cregan et al., 2002; Joza et al., 2001; Saelens et al., 2004; Susin et al., 2000). In normal 
cells, AIF is localised in the mitochondrial inner membrane and must be cleaved from 
the membrane in order to function in apoptosis (Otera et al., 2005). Once apoptosis is 
induced, AIF is then transferred to the nucleus (Daugas et al., 2000). The release of AIF 
from the mitochondria is antagonised by Bcl-2 proteins (Susin et al., 1996), and its 
transport to the nucleus is prevented by Hsp70 (Ravagnan et al., 2001). AIF triggers 
DNA condensation, large-scale DNA fragmentation and phosphatidylserine exposure on 
the plasma membrane. (Cande et al., 2002; Susin et al., 2000; Susin et al., 1999). 
Potentially, multiple pathways can converge on the mitochondria and cause the 
release of AIF (Yu et al., 2003). Most of these are still obscure. As one possible 
mechanism, caspase-2 can induce the release of AIF after p53 activation (Seth et al., 
2005). It has been shown that the release of AIF from the mitochondria can be initiated 
by poly (ADP-ribose) polymerase-1 (PARP-1) in response to DNA damage and cell 
stress (Koh et al., 2005; Yu et al., 2002). 
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2.3 Proteins involved in apoptotic DNA fragmentation and chromatin 
condensation 
DNA fragmentation and chromatin condensation are two characteristic features 
of apoptosis in most cells (Kerr etal., 1972; Wyllie, 1980). DNA fragmentation is a two-
step process that usually occurs in tandem with chromatin condensation. Large-scale or 
high molecular weight (HMW) DNA fragmentation (50-300 kb) precedes 
internucleosoma! (o!igonucleosomal) DNA fragmentation, which produces fragments 
that are multiplex of 180-200 bp (Cohen, 1997; Wyllie, 1980). Apoptotic chromatin 
condensation can be divided into two stages. At stage I, chromatin condenses against the 
nuclear periphery. Later, chromatin condensation proceeds to the formation of apoptotic 
bodies, termed stage II chromatin condensation (Samejima et al., 2001; Susin et al., 
2000). 
The degradation of cellular DNA was the first biochemical marker of apoptosis 
to be discovered, and it was proposed that an endonuclease is involved in the process of 
DNA fragmentation (Wyllie, 1980). Nearly 20 years passed, however, before the 
apoptotic endonuc!ease was identified and named CAD (caspase-activated 
DNAse)IDFF40/CPAN (Enari et al., 1998; Ha!enbeck et al., 1998; Liu et al., 1998; 
Sakahira et al., 1998). In cells, CAD nuclease is associated with its inhibitory chaperone, 
ICAD/DFF45 (Liu et al., 1998; Liu et al., 1997; Sakahira et al., 1998), which is now 
known as ICAD-L. 
CAD has been shown to be the main enzyme responsible for apoptotic 
internucleosomal DNA fragmentation and stage II chromatin condensation. It has also 
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been suggested that CAD participates in large-scale DNA fragmentation. The CAD 
knockout in chicken DT40 cells results in the loss of oligonucleosomal DNA 
fragmentation, while the high molecular weight fragmentation remains normal in cells 
exposed to etoposide (Samejima et al., 2001). Stage I DNA condensation occurs in the 
CAD knockout, while stage II DNA condensation, characterised by the formation of 
apoptotic bodies, is absent (Samejima et al., 2001). Similar data has been obtained in 
mouse ICAD and CAD knockouts, except that the large-scale DNA fragmentation was 
also abolished in the mouse CAD or ICAD knockout (Zhang et al., 2000) (Kawane et al., 
2003). CAD and ICAD will be discussed in greater detail in the next section. 
It has been noted that peripheral or stage I chromatin condensation still occurs 
during apoptosis even if caspases are inhibited, or in caspase-3 knockout cells, which 
fail to undergo CAD activation (Susin et al., 2000). It was shown that AIF can contribute 
to stage I chromatin condensation (Susin et al., 1999; Yuste et al., 2005), though the data 
on AIF involvement in high molecular weight DNA cleavage with the production of 50 
kb DNA fragments is more controversial. HMW DNA cleavage was observed if AIF 
was microinjected into HeLa cells (Susin et al., 1999). However, the depletion of AIF by 
RNAi did not prevent HMW DNA cleavage in apoptotic cells (Yuste et al., 2005), 
although the experimental data of this study showed that the depletion of AIF was 
incomplete. 
AlP's three-dimensional structure shows that it is associated with chromatin 
during the initiation of apoptosis and has a positive potential, which allows it to bind to 
negatively charged DNA (Ye et al., 2002). ALP can also interact with cyclophilin A and 
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cooperate to cause plasmid DNA cleavage or DNA degradation in isolated nuclei (Cande 
et al., 2004). 
Endonuclease G is a nuclease transported into the nucleus from the mitochondria 
during apoptosis (Li et al., 2001). In mouse embryonic fibroblast cells during the 
induction of apoptosis by ultraviolet irradiation and TNF, DNA fragmentation was 
noticed in wild type cells and in cells with the ICAD knockout (Li et al., 2001). 
However, in other studies, no clear DNA fragmentation was seen in ICAD knockout 
fibroblasts induced by TNF, etoposide, staurosporine or actinomycin D (Zhang et al., 
1998) (Zhang et al., 2003a; Zhang et al., 2000). It has been proposed, though, that 
endonuclease G acts in addition to CAD to cause internucleosomal DNA fragmentation 
(Li et al., 2001), and endonuclease G was also shown to be involved in DNA 
fragmentation in C. elegans (Parrish et al., 2001). Recent data render this claim is highly 
controversial, at least for mammalian cells. 
Two mouse endonuclease 0 knockouts show different phenotypes (Zhang et al., 
2003a) (Irvine et al., 2005). In one, the mouse develops normally and endonuclease G 
depletion does not interfere with apoptotic DNA fragmentation upon the induction of 
apoptosis with etoposide and actinomycin D (Irvine et al., 2005). In the other, the mouse 
dies during early embryonic development and the heterozygote is partly resistant to 
apoptotic cell death (Zhang et al., 2003a). Importantly, in the latter case, a part of the 
DNA adjacent to the endonuclease G gene was removed during knockout construction 
(Zhang et al., 2003a). This DNA encodes another gene with an unidentified function, 
whose disruption could potentially confound the endonuclease G depletion phenotype 
(Irvine et al., 2005). No oligonucleosomal DNA fragmentation was observed during the 
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activation of apoptosis by etoposide in the DT40 CAD knockout (Samejima et al., 
2001). This, however, does not exclude the possibility that different apoptotic stimuli, 
could activate different nucleases - particularly UV treatment for endonuclease G. 
Alternatively, the nuclease activated by UV irradiation in mouse ICAD knockout 
fibroblasts (Li et at., 2001) may not be endonuclease G. 
DNase II has been identified as an enzyme causing DNA fragmentation in 
thymocytes engulfed by macrophages (Kawane et al., 2003). In thymocytes, both 
DNAse II and CAD contribute to DNA fragmentation, and function cooperatively in this 
process. In addition to DNase II, DNase I had also been reported to take part in apoptotic 
DNA fragmentation in the human Jurkat cell line (Oliveri et al., 2001). However, this 
conclusion was not supported by the data from DNAse I knockout mice (Nagata et al., 
2003). DNAse gamma (Shiokawa and Tanuma, 1998) is another of the company of 
controversial apoptotic DNAses, and can induce oligonucleosomal DNA fragmentation 
in isolated nuclei in vitro (Mizuta et al., 2006). Whether DNAse gamma can function in 
vivo remains to be determined. 
In addition, the Acinus (apoptotic chromatin condensation inducer) protein has 
also been identified as the basis for chromatin condensation activity, as it can induce 
chromatin condensation in vitro on permeabillised HeLa cells (Sahara et al., 1999). 
Acinus has a nuclear localization and is activated by caspase-3 cleavage during the 
induction of apoptosis. Still, the involvement of Acinus in chromatin condensation is 
controversial; in one study, the depletion of Acinus by RNAi led to a decrease in 
chromatin condensation (Hu et al., 2005). However, these results are not supported by 
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another study, which suggests that Acinus depletion by RNAi does not interfere with 
chromatin condensation, but does reduce DNA fragmentation. (Joselin et al., 2006). 
2.4 The role and function of ICAD and CAD 
CAD and its inhibitor, ICAD, are broadly conserved across different species, 
from insects to humans, with orthologs even in cnidaria (Eckhart et al., 2007). Their 
prevalence may indicate their importance in apoptosis, DNA fragmentation and 
chromatin condensation. Most of the studies on ICAD and CAD proteins have been 
done on the mouse, human, chicken and rat proteins. 
2.4.1 ICAD-L, ICAD-S and CAD 
CAD is an endonuclease that is present throughout the cell cycle in a complex 
with ICAD (Enari et al., 1998; Sakahira et al., 1998). CAD is activated after the 
cleavage of ICAD by caspase-3 (Fig. 2.4). Activation of CAD during apoptosis causes 
the fragmentation of chromosomal DNA, and CAD, together with ICAD, was previously 
identified in humans as DNA fragmentation factor 40 (DFF40) and DNA fragmentation 
factor 45 (DFF45), respectively (Liu et al., 1998; Liu et al., 1997). 
One function of ICAD is to prevent the spontaneous activation of CAD. ICAD 
exists in cells in two splice forms: ICAD-L (long) and ICAD-S (short) (Kawane et al., 
1999). ICAD-L plays a role as not only an inhibitor, but also as a chaperone for CAD 
during its synthesis on the ribosome, and this chaperone function of ICAD-L is 
absolutely necessary for CAD to achieve its active conformation (Enari et al., 1998). If 
ICAD-L is added to CAD after CAD synthesis, the subsequent cleavage of ICAD-L by 
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promote CAD renaturation under reducing conditions in vitro (Sakahira et al., 2000). 
Chaperone Hsc70 and its co-chaperone, Hsp40, take part in this process (Sakahira and 
Nagata, 2002). When CAD is released from ICAD, its activity is stimulated by the 
presence of Hsp70 in vitro (Liu et al., 2003). ICAD-L was shown not only to be required 
for the synthesis of active CAD, but also for its stability in solution. CAD incubated 
without ICAD-L in vitro aggregates and becomes insoluble (McCarty et al., 1999b). 
Fig. 2.4. ICAD and CAD function. 
ICAD acts as a chaperone for 
CAD, promoting its folding to an 
active conformation on the 
ribosome. ICAD also functions as 
an inhibitor of CAD. After the 
activation of caspases during 
apoptosis, the ICAD is cleaved 
and active CAD is released. 
Active CAD dimer causes DNA 
cleavage. 
In contrast to ICAD-L, the role of ICAD-S is obscure. The ICAD-S form is 
formed by alternative splicing (Kawane et al., 1999). Both ICAD forms are able to 
inhibit CAD in vitro (Gu et al., 1999; Sakahira et al., 1999), though ICAD-L has been 
found in many cases to be the main form associated with CAD in vivo. The co-
expression of mouse ICAD-L and ICAD-S together with CAD in insect Sf-9 cells 
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demonstrated that CAD is principally associated with ICAD-L, while ICAD-S exists as a 
free form (Sakahira et al., 1999). However, in an in vitro transcription and translation 
system, human GST-ICAD-S can pull down more CAD than full-length ICAD (Gu et 
al., 1999). Moreover, in rat neurons, ICAD-S is the form associated with CAD in the 
nucleus, and ICAD-L has not been detected (Chen et al., 2000). ICAD-S is also the 
dominant form of ICAD detected in the rat, mouse and human central nervous systems 
(Chen et al., 2000). Therefore, determining which form of ICAD is mostly associated 
with CAD and the functional role of such association remains controversial. 
In recent research, it was reported that mouse and human ICAD-S does not have 
a chaperone function (Gu et al., 1999; Nagase et al., 2003; Sakahira et al., 1999). 
Nevertheless, low chaperone activity has been claimed for ICAD-S (Scholz et al., 2002). 
In one study ICAD-S promoted the formation of active CAD in E. coli, but its activity 
was, however, 40- to 50-fold lower than that produced with ICAD-L. Therefore, the 
actual ICAD-S function in vivo required further clarification during my study. 
2.4.2 ICAD and CAD regulation 
The main mechanism of CAD regulation is provided through the cleavage of 
ICAD by caspase-3 after the induction of apoptosis (Fig. 2.5). ICAD-L and ICAD-S are 
cleaved by caspase-3 at two sites, releasing three polypeptides (Sakahira et al., 1998). 
Mutation of the caspase-3 cleavage sites in ICAD-L demonstrated that the cleavage of 
both sites is necessary for the release of CAD from ICAD-L. The cleavage of the first 
caspase-3 site of ICAD-S is enough to release and activate CAD, however, even if the 
second caspase-3 site is not cleaved (Sakahira et al., 1998). 
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Fig. 2.5. ICAD and CAD proteins. ICAD-L and ICAD-S proteins have two cleavage sites for 
caspase-3. Also, ICAD-L has a nuclear localization signal (NLS) on the C-terminal end. ICAD-L 
C-terminal domain is disrupted in ICAD-S. However, ICAD-S has a small fragment with 
unidentified function encoded by alternatively spliced mRNA. ICAD and CAD proteins share a 
homologous CIDE N-terminal domain. In addition, CAD has C2 and C3 domains and an NLS on 
its C-terminus. 
Another effector caspase, caspase-7, has been shown to cleave both ICAD sites if 
added to reactions in vitro (Liu et al., 1999; Mcllroy et al., 1999). However, an 
endogenous caspase-7 activity from MCF7 cell line extracts lacking caspase-3, was not 
able to cause ICAD cleavage nor DNA fragmentation on isolated nuclei (Wolf et al., 
1999). 
ICAD can be also cleaved in vitro and in vivo by the serine proteinase granzyme 
B, with subsequent CAD activation and DNA fragmentation (Thomas et al., 2000). 
Granzyme B is released from granules of cytotoxic T-lymphocytes as one mechanism of 
killing target cells. ICAD cleavage by granzyme B can be done either by activating the 
apoptotic pathway through caspase-3 cleavage or by direct ICAD cleavage, as was 
shown in the presence of caspase inhibitors (Sharif-Askari et al., 2001). Granzyme B can 
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also initiate other pathways independent of ICAD and leading to cell death (Thomas et 
al., 2001). 
2.4.3 Additional putative CAD inhibitors 
B23fNucleophosmin has been reported to inhibit CAD. B23 is a protein involved 
in ribosome biogenesis in the nucleolus (Savkur and Olson, 1998), and has chaperone, 
ribonuclease and nucleic acid binding activity (Hingorani et al., 2000). B23 was shown 
to inhibit CAD in vitro, and, if overexpressed, in vivo. The inhibitory action of B23 was 
in response to a second messenger, phosphatidylinositol 3,4,5-triphosphate (Ahn et al., 
2005). 
However, B23 can bind NLS containing peptides with high affinity and 
participate in nuclear importation (Szebeni et al., 1995). This, and the fact that B23 has 
chaperone activity (Szebeni and Olson, 1999), may mean that the association of B23 
with CAD via its NLS might have implications for nuclear transport or chaperoning. 
A protein named CIIA has also been identified as a CAD interactor (Cho et al., 
2003). CIIA was shown to interact with CAD in vitro and in the ICAD:CAD complex, 
but not with ICAD alone. CIIA was also found to inhibit CAD activity after ICAD 
destruction in vitro and during overexpression in 293T cells. 
2.4.4. Modulators of ICAD and CAD function 
Histone Hi and high mobility group (HMG) proteins I and 2 can stimulate the 
cleavage of naked plasmid DNA by CAD in vitro (Liu et al., 1998; Toh et al., 1998). 
These proteins bind to nucleosomal linker DNA (Schroter and Bode, 1982). It was 
proposed that histone HI, HMG-1 and HMG-2 may target CAD to nucleosomal linkers 
and stimulate its catalytic activity (Liu et al., 1998; Liu et al., 1999), but it has been 
noticed that the degree of CAD stimulation was significantly lower on chromatin than on 
naked DNA in vitro (Widlak et al., 2000). 
CAD can also interact with topoisomerase ha (Durrieu et al, 2000), and was 
shown to stimulate CAD activity on naked DNA, though not on chromatin. 
Topoisomerase ha also contributes to chromatin condensation during apoptosis 
(Durrieu et al., 2000). 
2.4.5 Proteins with CIDE domain 
ICAD and CAD proteins have a homologous N terminal domain, the CIDE 
domain (cell death inducing FF45-like effector). Interestingly, a homologous N-
terminal domain has also been found in three other human proteins: CIDE-A, CIDE-B 
and CIDE-C/CIDE-3/FSP-27 (Danesch et al., 1992; Inohara et al., 1998; Liang et al., 
2003). In addition to the N-terminal domain, CIDE proteins also contain a C-terminal 
domain different to that of ICAD or CAD. The expression of these proteins can be 
tissue-specific (Da et al., 2006; Inohara et al., 1998). CIDE proteins have been found to 
stimulate apoptosis and cause DNA fragmentation and condensation upon 
overexpression in 293T cells (Inohara et al., 1998). Their CIDE domain can interact with 
the similar domain of ICAD and CAD in vitro (Lugovskoy et al., 1999). Interestingly, 
hepatitis C virus NS2 protein can inhibit apoptosis through action on CIDE-B's C-
terminal domain (Erdtmann et al., 2003). Whether interaction of CIDE proteins with 
ICAD and CAD has a physiological role remains to be determined. 
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CAD splice variants have also been reported in a variety of human and mouse 
tissues (Bayascas et al., 2004). The three CAD splice forms identified correspond to the 
N-terminal CIDE domain of CAD alone or to the CIDE domain with approximately 
thirty additional amino acids on its C-terminus. These short CAD forms were shown to 
interact with ICAD in vitro (McCarty et al., 1999a). This interaction, therefore, has a 
structural basis, but it is not clear whether CAD splice forms have a physiological 
function in vivo. 
2.4.6 Additional putative mechanisms of ICAD and CAD regulation 
It has been claimed that there is less ICAD-L protein in cell tissues that express 
less CAD protein, though the amount of ICAD-S remains unchanged (Nagase et al., 
2003). Moreover, in CAD knockout cells, the amount of ICAD-L protein was reduced as 
compared to wild—type cells. While the amount of ICAD-L protein was reduced in the 
CAD knockout, the amount of ICAD-L niRNA was not affected. This study therefore 
suggests that the regulation of ICAD-L protein levels may occur at the post-
transcriptional level (Nagase et al., 2003). The reduced amount of ICAD-L protein in 
the CAD knockout may be explained by the possibility that ICAD-L, if not in complex 
with CAD, is a more likely target for protein degradation. 
In addition to possible ICAD posttranslational modifications, some data propose 
that CAD be can down-regulated and degraded once apoptosis is induced and ICAD is 
cleaved (Lui and Kong, 2006; Yuste et al., 2001). The disappearance of CAD shortly 
after caspase-3 cleavage of ICAD has been noticed in the human neuroblastoma IMR-5 
cell line (Yuste et al., 2001). Apoptosis proceeded in this cell line without characteristic 
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DNA fragmentation. It must, however, be noted that there is a cell line variability on the 
presence of DNA fragmentation in different neuroblastoma cell lines (Boix et al., 1997). 
The DNA fragmentation was restored in the IMR-5 cell line after the overexpression of 
CAD (Yuste et al., 2001). 
Caspase-3 could be involved not only in apoptosis, but also in erythropoiesis 
(Carlile et al., 2004). Caspase-3 activation can also cause a partial cleavage of ICAD 
during erythroid development (Lui and Kong, 2006), though no DNA fragmentation was 
observed. Interestingly, it was noticed that the levels of both CAD mRNA and protein 
were decreased by an unknown mechanism in these cells. 
2.4.7 ICAD and CAD localization 
To participate in DNA fragmentation, CAD must have access to the DNA in the 
nucleus. A nuclear localization signal has been identified on the C-terminus of ICAD 
and CAD (Enari et al., 1998; Liu et al., 1998; Samejima and Earnshaw, 1998), but the 
nuclear localisation signal is absent in ICAD-S, which is distributed diffusely in cells 
(Lechardeur et al., 2000; Samejima and Earnshaw, 2000). 
The localisation of ICAD-L and CAD is controversial. The papers assessing 
ICAD and CAD localisation by immunostaining of tagged ICAD and CAD proteins 
make claims for ICAD and CAD nuclear localisation (Lechardeur et al., 2000; Liu et al., 
1998; Samejima and Earnshaw, 2000). In contrast, the data from the experiments in 
which the cytoplasmic and nuclear fractions were analysed for the presence of ICAD 
and CAD shows that these proteins have mostly cytoplasmic localisation (Durrieu et al., 
2000; Enari et al., 1998; Mitamura et al., 1998). However, the occurrence of ICAD and 
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CAD in the cytosolic extracts may be the result of their leakage from the nuclei during 
the biochemical purification procedure (Liu et al., 1998). 
2.4.8 The three-dimensional structure of ICAD and CAD 
The structure of CAD had been solved first for its N-terminal domain (Uegaki et 
al., 2000; Zhou et al., 2001), and then for the rest of the protein (Woo et al., 2004). The 
N-terminal CIDE domain, which is homologous in ICAD and CAD (Fig. 2.6), consists 
of one a-helix and five p-strands organised in a 3-sheet with two hydrophobic clusters 
situated on opposite sides (Uegaki et al., 2000). 
A 	 B Fig. 2.6. The three-dimensional structure of ICAD 
and CAD N-terminal (CIDE) domains solved by 
NMR. (A) CIDE domain of ICAD has a structure 
consisting of one a-helix and one 3-sheet from five 
3 strands. (B) CAD CIDE domain. The difference 
between ICAD and CAD CIDE domains is in a 
short helical element present in ICAD and disrupted 
in CAD. CAD and ICAD CIDE domains also differ in 
the angle between u-helix and 3 strands (Adapted 
from (Zhou et al., 2001)). 
The middle and C-terminal part of the CAD protein was crystallised (Woo et al., 
2004) and is shown on Fig. 2.7. ICAD blocks the ability of CAD to bind DNA (Sakahira 
et al., 2001). After ICAD cleavage, CAD protein is liberated and forms a homodimer. 
Zinc was shown to be crucial for homodimer formation and stability. The CAD 
homodimer has a crevice formed between two C-terminal (C3) domains of CAD protein, 
which accommodates and cleaves double-stranded DNA (Woo et al., 2004). This crevice 
is thought to be inaccessible to DNA packaged into nucleasomes, which could allow 
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only the free internucleosamal DNA to be cleaved. As a result, the characteristic 
oligonucleosomal DNA cleavage of about 200 bp would be produced. 
H242 
] 
Fig. 	2.7. 	The 	three- 
dimensional structure 	of 
mouse CAD middle (C2 
domain) and C-terminal part 
(C3 domain). The C2 domain 
consists of three a-helixes, 
while the C3 domain consists 
of five a-helixes and four 3-
strands in addition to a long C-
terminal loop with a nuclear 
localization signal. In a 
homodimer form, two CAD C3 
domains form a crevice 
surrounding DNA (Adapted 
from (Woo et al., 2004)). 
The ICAD protein CIDE domain structure (Fig. 2.6A) is similar to that of CAD 
(Otomo et al., 2000; Zhou et al., 2001). While the structure of the ICAD middle part 
remains to be determined, the ICAD C-terminal domain (Fig. 2.8) has a unique structure 
of four a-helixes, one of which ((xl) is situated perpendicularly to the other three a-
helixes (Fukushima et al., 2002). It was suggested that in ICAD-S the unique 
organisation of the C-terminal domain is disrupted (Fukushima et al., 2002), and as a 
result, human ICAD-S cannot completely provide its chaperone function for human 
CAD (Fukushima et al., 2002). 
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AL Fig. 2.8. The structure of the human ICAD 
C-terminal domain. It has a unique 
structure of four a-helixes. (Adapted from 
Fukushima et al., 2002) 
2.4.9 Physiological role of the DNA cleavage by CAD for an organism 
Pathways leading to CAD activation and DNA fragmentation were shown to be 
specific to cells dying by apoptosis. Several reasons have been suggested to explain the 
importance of this pathway for an organism. 
Cleavage of DNA into smaller pieces may be an important step to reduce the 
influence of the dead cells' DNA uncoiling on the neighbouring cells (Wyllie, 1998). 
DNA fragmentation can also eliminate viral DNA in the case of viral infection. In 
transformed cells undergoing apoptosis, the degradation of DNA may also prevent the 
potential releasing of DNA containing oncogenes and its transformation to healthy cells. 
Macrophages can be particularly sensitive to foreign DNA, as they engulf cells that 
contain viruses or transformed cells with oncogenes. That can partly explain why 
macrophages have an alternative to the CAD pathway for causing DNA fragmentation 
with DNAse H in engulfed cells (Kawane et al., 2003). In addition, DNA produced 
during massive cell death can act as an autoimmunogen. Therefore, the cleavage of 
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DNA to oligonucleosomal fragments may prevent an autoimmune reaction (Nagata, 
2000). 
2.4.10 CAD role in cell death. 
CAD does not appear to be essential for apoptotic cell death. Caspase-3, 
ICAD' or CAD' cells still die after the activation of apoptosis (Janicke et al., 1998; 
Sarnejima et al., 2001; Woo et al., 1998; Zhang et al., 1999). This implies that CAD is 
dispensable for cell death, but does not explain CAD's role in cell death. Therefore, I am 
interested in investigating the particular role of CAD in this process. 
Indirect data has been obtained to support the hypothesis that CAD activation 
can lead to cell death. Mouse thymocytes and fibroblasts lacking the ICAD' gene were 
reported to be more resistant to a number of proapoptotic stimuli than were cells with the 
intact JCAD' gene (Boulares et al., 2001; Thomas et al., 2000; Zhang et al., 1999). A 
delay in cell death in the fibroblasts of ICAD' mice could imply the contribution of 
CAD to this process. 
Cleavage of DNA by CAD produces double-strand breaks that can act as 
apoptotic signals (Liu et al., 1999). DNA breaks can be detected by PARP. It has been 
noticed that after the induction of apoptosis by TNF in ICAD fibroblasts, a significant 
delay occurs in PARP activation relative to what is seen in wild type fibroblasts 
(Boulares et al., 2001). This is also supported by the fact that DNA cleavage by CAD 
can facilitate apoptosis in a positive feedback loop (Ben-Yehudah et al., 2003). In 
addition, it has been shown that a chimeric CAD protein consisting of CAD linked to 
gonadotropin-releasing hormone can cause cell death in adenocarcinoma cells through 
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DNA damage, which causes the subsequent activation of apoptosis (Ben-Yehudah et al., 
2003). After targeting cells with chimeric CAD protein, cytochrome c was shown to be 
released from the mitochondria with the subsequent activation of caspase-9 and caspase-
3. However, this experiment did not use native CAD protein, and therefore the question 
of whether this process takes places in vivo under physiological conditions is still 
uncertain. 
CAD is activated at the end of the apoptotic signalling pathway. Therefore, if it 
could be directly activated to kill the cell, it might escape regulation by the complex 
apoptosis machinery. CAD activation in vivo could be done by discovering compounds 
that disrupt the interactions between ICAD and CAD. In addition, ICAD could be 
destroyed in model system in vivo if specially targeted for disruption. Therefore, a part 
of my PhD project aim was to create a model system for ICAD destruction and discover 
if in vivo activation of CAD is enough to kill the cell. 
2.4.11. Project aims. 
The specific questions I wished to address in my PhD study are: 
Can CAD activation in vivo cause cell death in the absence of initial apoptosis? 
To answer this question, it was necessary to create a model system for the 
specific destruction of ICAD in DT40 cells. The development of such a system 
involving site-specific protease, which has not been done before in vertebrate 
cells, was another aim of my study. 
What is the role of the ICAD-S splice form in vivo and can it work as a 
chaperone and inhibitor for CAD in the absence of ICAD-L? 
3. Materials and Methods 
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3.1 Chemicals and common solutions 
All chemicals used in this study were from Sigma-Aldrich, unless otherwise 
indicated. Restriction enzymes and other enzymes for molecular cloning were from New 
England Biolabs (NEB). Luria-Bertani medium (LB) pH 7.0 is 1 % tryptone, 0.5 % 
yeast extract, 1% NaCl. Low-salt LB (1 % tryptone, 0.5 % yeast extract, 0.5% NaCl) 
was used for the selection of zeocin resistance plasmids in E. coli. Phosphate-buffered 
saline (PBS) is 137 mM NaCl, 2.7 mM KCI, 10 mM Na2HPO4, and 2 mM KH2PO4. 
3.2 Molecular biology 
3.2.1 Molecular cloning 
DNA for molecular cloning was digested with the appropriate restriction enzyme 
for one to four hours at 37°C, following the manufacturer's instructions. Vectors were 
treated with 10 units of calf intestine phosphatase for one hour at 37° C to prevent self-
ligation. The DNA fragments in gel loading buffer (0.04% Bromophenol Blue, 5% 
glycerol) were separated on 0.8 - 2.5 % agarose gels, depending on the product size. 
The agarose gels contained 0.5 jtg/ml ethidium bromide in TAE buffer (40 mM Tris-
acetate, pH 8 ; 1 mM EDTA). DNA ladders I kb (Invitrogen) and 100 bp (NEB) were 
used as size markers. The gels were visualised on a UV transilluminator, and the DNA 
fragments were purified from the agarose gels using a QlAquick Gel Extraction Kit 
(Qiagen). The DNA products were ligated with 400 U of T4 DNA ligase (NEB), either 
for one hour at room temperature for cohesive end termini or at 16° C overnight for blunt 
end ligations. The ligation products were transformed into competent E. coli and 
selected with the appropriate antibiotic: ampicillin (100 jig/ml), kanamycin (50 jig/ml), 
ME 
or zeocin (25 [tg/ml). The list of vectors used and constructed in this study is 
summarised in Table 1. 
Table 1. Cloninq of codincj sequences and construction of tarqetinq vectors 
Construct Coding Vector Restriction sites Source, PCR or cloning, 








targeting pBluescript 11 (Samejima et al., 2001) 





pBluescript II BamHl/BamHl Cloning from AA4.1 
KS (+) vector  






AA4.5 genomic X FIX II Dr. Kumiko Samejima 
region  
pBluescript II 
PCR: KS23/KS24 from 
AA4.6 3' ICAD arm 
KS 
Spel/Noll AA4.5 and digest 
Spel/Noll Cloning into AA4.4 
pBluescript II 
BamHl/Baml-41 Cloning of AA4.5 
AA4.7 5' ICAD arm 
KS (+) 
Kpnl/Ncol* 
KpnlIHinc II* into AA4.4 
AA4.8 5'-3' ICAD pBluescript II 
SpelINoll Cloning of AA4.6 
Arms KS (+) SpeI/Noll into AA4.7 
AA4.9 Tk pBT/SP-TK  Prof. Adrian Bird 
AA4.10 loxP-puro- pLoxPuro 
loxP  
(Arakawa et al., 2001) 
AA4.1 1 IoxP-puro-tk- p LoxPuro 
Xbal/XbaI Cloning of AA4.9 
IoxP Nhel into AA4.10 
ICAD 
targeting 
pBluescript II BamHl/BamHI Cloning from AA4.1 1 
AA4. 12 vector 
KS BamHl into AA4.8 
loxP-puro-tk- 





pBluescript II BamHl/BamHl Cloning from AA4.10 
loxP-puro- KS (+) 
BamHl into AA4.8 






pGEM-T- Direct PCR PCR: KS5/KS6 from 
Easy product cloning HeLa RNA 
AA4.16  pZeoSV2+ 	I  Invitrogen 
AA4.17 hICAD-L pZeoSV2~ 
Noll/Noll Cloning from AA4.15 
Not! into AA4.16 
41 
AA4.18 hCAD 
pGEM-T- Direct PCR PCR: KS7IKS8 from 
Easy product cloning HeLa RNA 






PCR: Sal l/Sa12 Easy 
site  mutagenesis 
hICAD-L Klenow polymerase 
AA5.2 with 1st TEV 








with 1StTEV pZeoSV2~ 
No/I/No/I Cloning from AA5.2 
site  
No/I into AA4.16 
hICAD-L Klenow polymerase 
AA5.4 fragment with pGEM-T- Direct reaction synthesis: Sa21/Sa22 
2 ° TEV site 
Easy product cloning and treatment with TakaRa 
LA Tag 
hICAD-L 
fragment with pGEM-T- Direct PCR PCR: Sa26/Sa27 from 
2 	TEV site Easy product cloning AA5.4 
extension  
AA5.6 hlCAD-L2T ' pZeoSV2+ 
Eail/BIpl Cloning from AA5.5 
Eail/BIpl into AA5.3 
AA5.7  pECE  (Ellis et al., 1986) 




BamHl Cloning from AA5.7into 
(incomplete AA5.7 
digest)  
AA5.10 hCAD pECE-His 
No/I/No/I Cloning from AA4.18 
No/I into AA5.9 
MS. 11 rtTA pTet-On  Clontech 
AA5.12 	I TEV Yip204  (Uhlmann et al., 2000) 
(Manfred Gossen- 
AA5.13 pUHD10.3 unpublished, ZMBH, 
Heidelberg) 
PCR: Sa36/Sa37 from 
M5.14 TEV pUHD10.3 EcoRl/Xbal AA5.12 and digest 
EcoRl/Xbal into AA5.13 
AA5.15 MBP-mTEV pRK793  (Kapust et al., 2001) 
M5.16 
MBP-mTEV pGEM-T- Direct PCR PCR: Sal 15/Sal 16 from 
with 21NILS Easy product cloning AA5.15 
M5.17 
pUHD10.3- 
Dr Kumiko Samejima 
RFP  
AA5. 18 
MBP-mTEV pUHD10.3- EcoRl/EcoRl Cloning from AA5.16 
with 21NILS RFP EcoRl into AA5.17 
AA5.19 PreScission pGEX-1N  (Leong et al., 1992) 
AA5.20 PreScission 
pGEM-T- Direct PCR PCR: Sal 84/Sal 85 from 
Easy 	I product cloning AA5.19 
AA5.21 PreScission pECE-His 
No/I/No/I Cloning from AA5.20 
No/I into AA5.9 
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AA5.22 PTracer- Invitrogen __________  SV40 
AA5.23 PreScission 
Plracer- NoIl/NolI Cloning from AA5.21 
SV40 Nog into AA5.22 
AA5.24 
hlCAD-' L pGEM-T- Direct PCR PCR stepl:Sa178/Sa179 
__ fragment Easy product cloning PCR step2:Sa181/Sa183 
AA5.25 WCAD-L 2PRE 
pGEM-T- Eatl/BIpl Cloning from AA5.24 
Easy Eaii/BIpl into AA5.1 
AA5.26 hICAD-L2PRE  PZeoSV2+ 
NoINofl Cloning from AA5.25 
NotI into AA4.16 
cICAD-L 
AA6.1 incomplete pBluescript Dr. Kumiko Samejima 
cDNA  
AA6.2 cICAD-L pGEM-T- Direct PCR PCR: Sa72/Sa54 




pGEM-T- Direct PCR PCR: Sa72/Sa56 
codone 
Easy product cloning from AA6.1 
AA6.4 double tag pcDNA3.1/ Dr. Sandrine Ruchaud (S-TEV-SBP) Hygro 
SATH tag 
Cloning of annealed Xhol cut 
AA6.5 
C-terminal pcDNA3.1/ Xhol/Xhol 
primers Sa75/Sa76 (S-TEV-SBP- Hygro (+) Xhol 
His) into AA6.4 
AA6.6 
cICAD-L- pcDNA3.1/ Noll/NotI Cloning of AA6.3 
SATH tag Hygro (+) Nog into AA6.5 
AA6.7 cICAD-S 
pGEM-T- Direct PCR PCR: Sal 50-Sal 32 from 
Easy product cloning cICAD fragment 
AA6.8 cICAD-S pZeoSV2+ 
Nod/Nog Cloning from AA6.7 
Notl into AA4.16 
AA6.9 _________  cCAD 
plracer- 
SV40 Dr Kumiko Samejima 
AA6.10 hICAD-S pGEMT-Easy 
Direct PCR PCR: Sa81/Sa121 from 
product cloning into AA4.15 
AA6.11 hICAD-S pZeoSV2+ 
NotI/NotI Cloning from AA6.10 
Notl into AA4.16 
AA6.12 hlCADS2TEv pGEM-T- Direct PCR PCR: Sa81/Sa121 from 
Easy product cloning AA5.6 
AA6.13 hICADS2TEI  pZeoSV2+ NofliNotI Cloning from AA6.12 
Noll into AA4.16 
AA6.14 hICAD-S 
pcDNA3.1/ Hinolll/Xhol Cloning of AA6.1 1 
Hygro (+) Hindlll/Xhol into AA6.5 
AA6.15 hICADS2TEV pcDNA3.1/ Hindlll/Xhol Cloning of AA6.13 
Hygro (+) Hinolll/XhoI into AA6.5 
'-Indicates that the site was blunt-ended before ligation 
3.2.2 Partial digestions 
To isolate a DNA product with a single cut from a plasmid containing two 
restriction sites, partial digestion was used. The restriction enzyme was diluted at 
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different concentrations (0.25, 0.5, 1, and 2 U) per 1 .tg of plasmid DNA. The reaction 
was incubated for 30 minutes at 37° C. The reaction products were separated on agarose 
gels and gel purified using a QlAquick Gel Extraction Kit (Qiagen). 
3.2.3 Blunting the end of DNA fragments 
T4 DNA polymerase (NEB) was used to create blunt ends after restriction 
digestion. 1.5 U per I ig of DNA was used in a reaction supplemented with 100 1iM of 
dNTP mix. The reaction was carried out for 15 minutes at 37° C, then the T4 DNA 
Polymerase was heat inactivated for 20 minutes at 70° C. The reaction products were 
separated on agarose gels and gel purified using a QlAquick Gel Extraction Kit 
(Qiagen). 
3.2.4 Preparation of competent E. coli and transformation 
E. coli strains ToplO and DH5a were used to make competent cells. The E. coli 
culture (5 ml) was grown overnight in LB medium with ampicillin. The culture was then 
diluted 1:200 in LB medium with ampicillin and incubated with shaking at 37° C until 
0D600 0.48 was reached. The cells were chilled on ice for 10 minutes and then pelleted 
by centrifugation for five minutes at 2700 x g at 4° C. Then the pellet was resuspended 
in 40 ml of TfbI buffer (30 mM CH3COOK; 100 mM RbC12; 10 mM CaCl2; 50 mM 
MnC12; 15% Glycerol; pH adjusted to pH 6.5 using KOH) per 100 ml of bacterial 
culture. The cells were incubated on ice for five minutes, then centrifuged at 1000 x g 
for 10 minutes. The supernatant was discarded and the cells were resuspended in 4 ml 
TbfJI buffer (10 mM Mops; 75 mM CaCl2; 10 mM RbC12; 15 % (w/v) glycerol; pH was 
adjusted to 6.5 with KOH). The 100-200 j.tl aliquots were snap frozen in liquid nitrogen 
for storage at -80° C. The TIbI and TIbH buffers were filter sterilised before use. 
To transform E. coli cells, the aliquots of competent cells were thawed on ice and 
mixed with the ligation mixture. The samples were left incubated on ice for 30 minutes, 
and the the mixture was heat shocked at 42° C for two minutes and chilled on ice for 
three minutes. The cells were incubated with an additional 1 ml of LB medium on a 
shaker for one hour at 37° C, then spread on agar plates with the selection antibiotic. 
3.2.5 Isolation of plasmid DNA 
The colonies of E. coli cells after transformation were grown in LB medum with 
the appropriate antibiotic for 12 to 16 hours at 37° C. Plasmid DNA was isolated using 
the plasmid purification kits FastPlasmid Mini (Eppendorf), QlAfilter Midi (Qiagen), 
and QIAfilter Maxi (Qiagen), according to the amount of DNA required. Purifications 
were performed according to the manufacturers' instructions. The DNA concentration 
and quality was determined on a Beckman DU530 Spectrophotometer by reading the 
absorption at 260 and 280 nm. 
3.2.6 PCR 
Oligodeoxynucleotides for PCR reactions were synthesized by Sigma-Genosys 
(Table 2). The PCR reactions were performed with TaKaRa LA Taq (Takara Bio Inc.), 
Taq polymerase (Roche), or PfuTurbo (Stratagene) according to the manufacturers' 
instructions. 
TaKaRa polymerase was used in a mixture (30:1) with PfuTurbo for PCR 
amplication of fragments over I kb where high fidelity was required. 
Table 2. PCR orimers emDloved in this study 
Primer name Primer sequence 
Used to
construct 
KS5 hICADs fw 5'-AGCTCTAG AATG GAG GTGACCG-3' AA4.15 
KS6 hiCAD a rv 5'-AGCGAATTCCTATGTGGGATCCTG-3' AA4.15 
KS7 hCADs fw 5'-AGCTCTAGAATGCTCCAGAAGCCC-3' AA4.18 
KS8 hCAD a rv 5'-AGCAAGC1TrCACTGGCGTTTCCG-3' AA4.18 
KS1 3 ICAD fw 5'-ATCCAAACATAAGCATGT-3' 
5' probe s 
KS1 4 ICAD rv 5'-ATGTTGTGTTAGTATGGG-3' 
5' probe a 
KS1 5 ICAD fw 5'-CAAGAAAGCAAGTAGTGG-3' 
3' probe s 
KS1 6 ICAD rv 5'-TTATAAACA I I I I CCTTT-3' 
3' probe a 
KS23 cICAD 3arm s fw 5'-ACTACTAGTGCATGCGACTATAGTTCTGCC-3' AA4.6 
KS24 cICAD 3arm a rv 5'-ACTGCGGCCGCAAGTTCATGAc3c3C1TVGTG-3' AA4.6 
Sall TEV-EV fw 5'-GGTACAGCTTGGATATCCCAAGAGTCC-3' AA5.1 
Sal 2 TEV-EV rv 5'-GGACTCTTGG GATATCCAAGCTGTACC-3' AA5. 1 
Sa18 TEV1 a rv 5'-TGGACAGATCTTCUTCAGCTGCCTGGCCAC AA5.2 ATTCUCCACUCAACCCTGCCCCGC-3'  
fw 5'-GCCTCTrGTCAAAGCAGGAAGAGTCCAAAGCT 
Sa21 TEV2 s GCCTUGGTGAGGAGGTGGAGMCCTCTACTTCCA AA5.4 GAGCGACACGGGTATCAGCAGAGAGACCTCCTC 
G-3'  
rv 5'-CCTGACTAGATAAGCTCAGCTCTGGAGCCTGC 
Sa22 TEV2 a UCTCCCTCAGTGCAGTAAGGATGTGGCTCGCCAG AA5.4 
CGCAACGTCCGAGGAGGTCTCTCTGCTG-3'  
fw 5'-GCTTGGATATCCCAAGAGTCCTTTGATGTAGA 
Sa25 TEV1 s GAACCTCTACTTCCAGAGCGACAGCGGGGCAGGGT AA5.2 
TGAAGTGG-3'  
Sa26 TEV2 short s fw 5'-GCCTCTTGTCMAGCAGGAAGAGTCCAAAGC AA5.5 TGCC1TrGG-3'  
Sa27 TEV2 short a rv 5'-CCTGACTAGATAAGCTCAGCTCTGGAGCCTG AA5.5 CTTCTCCCTCAG-3'  
Sa36 TEV-Tet-On s fw 5'-CCGGAAUCATGCCAAAGAAGAAGCGTAAGG- AA5.14 3,  
Sa37 TEV-Tet-On a rv 5'-GCTCTAGATTAATCAAC I I I I CGTTTC AA5. 14 
Sa54 cICAD cDNA a rv 5'-TTA TTT UT GCG TTT TGA ACT AAG CCC-3' 
AA6.2 
Sa56 cICAD-cDNA- rv 5'-ATAGlTrAGCGGCCGCC UT UT GCG UT 
no stop a TGA ACT AGC CC-3'  AA6.3 
fw 5'-ATGGCGGCGCGGCTGMGCCGTGCGTGGT 
Sa72 cICAD s GCGGCGGGGCGACGGGCGCGAGCAGCACGGGCT AA6.2 
GGCCGCC-3'  AA6.3 
Sa75 6Hs S fw 5'-ACCCGCTCGAGGGCATCACCATCACCATCA AA6.5 CCTCGAGCCACAC-3'  
Sa76 6His a rv 5'-GTGTGGCTCGAGGTGATGGTGATGGTGATG AA6.5 CCCTCGAGCGGGT-3'  
Sa81 hICADs fw 5'-ATAAGAAGCGGCCGCATGGAGGTGACCGGG-3' AA6. 10 
AA6. 12 
Sal 15 MBP-TEV s fw 5'-TCAGGGAAUCATGAAAATCGAAGAAGGTAAA 
CTGG-3'  AA5. 16 
rv 5'-TCAGGGAAUCUAUATAC I I I I CGUTCU 
Sal 16 MBP-TEV a 1111 GGTACTUTCGTTTC II I III GGAUCATGAG AA5.16 
UGAGTCGC-3'  
IR 
Sal 21 hICAD-S a rv 5'-ATGGGCGGCCGC TCAGTGACC CTGGTTTCC AA6.10 
GCCCACCTCCAAATCCTGACTAGATAAGCTC-3' AA6. 12 
rv 5'-CTGGGCGGCCGCTCAACCCCTTCTCCAc3ATAG 
Sal 32 cICAD-S a GTGAGA1TVGCCAGAACATGGTGTATGATCCTCAC AA6.7 CCACCTCTAGAGTrTGACTGTCC-3' 
fw 5'-AACTAGCGGTACCATGGCGGCGCGGCTGAAG 
Sal 50 cICAD-S s CCGTGCGTGG-3' AA6.7 
fw 5'-GGATATCCCAAGAGTCCTrTGATGTAcTcGAA 
Sal 78 ICAD-Pre s GTTCTC1TCAAGGACCCAGCGGGGCAGGGTTGAA AA5.24 GTGG-3' 
rv 5'-AGTGCAGTAAGGATGTGGCTCGCCAGCGCAAC 
GTCCGAGGAGGTCTCTCTGCTGATACCCGTGGGTC 
Sal 79 ICAD-Pre a CTGAAAGAGAACTTCGAGCACCTCCTCACCAAAGG AA5.24 
CAG-3' 
Sal 81 [CAD-Pre-sm fw 5'-GGATATCCCAAGAGTCCTTTG-3' 
AA5.24 
S 
Sal 83 ICAD-Pre-sm rv 5'-AGCTCAGCTCTGGAGCCTGCTTCTCCCTCAGT 
GCAGTAAGGATGTc3c3-3' AA5.24 a 
Sal 84 PreScission s fw 5'-TCAGGGAATTCATGTCCCCTATACTAGGTTAT AA5.20 TGG-3' 
Sal 85 PreScission a rv 5'-TCAGGGAATrCTCATTGlTrcTCTAcAAAATA AA5.20 TTG I I I I 	I AAGTTGAGCTG-3' 
3.2.7 Introduction of EcoRV site into hICAD-L by site-directed mutagenesis 
The QuikChange Site-Directed Mutagenesis Kit (Stratagene) was used to 
incorporate an EcoRV site into hICAD-L cDNA (construct AA5.1). The reaction was 
performed according to the manufacturer's instructions with primers Sal I and 5a12. 
3.2.8 Construction of hICAD-L2Tf 
To construct hICAD-L with two TEV sites (hICAD-1 2T '), DNA Polymerase I, 
Large (Kienow) Fragment (NEB) was used (see chapter 5.2 and Fig. 5.2). Two long 
DNA oligos (2 tg each) were boiled for 10 minutes in Klenow buffer (0.01M Tris 
pH7.7; 0.05 M M902;  0.001M DTT; lx BSA (NEB)). The reaction was cooled slowly 
to 37° C to allow oligo annealing. Kienow (40U) was added, together with 10 Id 
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of a 10 mM solution of each dNTP, bringing the total volume of the reaction to 50 iil. 
The reaction was incubated at 37° C for two hours, and then the reaction products were 
separated in a 2.5% agarose gel and purified. The hICAD-L fragment containing the first 
TEV site (from oligos Sa25 and Sal 8) was digested with EcoRV and BglII enzymes and 
used to replace the corresponding fragment of hICAD-L, containing the caspase-3 site, 
yielding AA5.1 construct (Table 1). The hICAD-L fragment containing the second TEV 
site (from oligos Sa21 and Sa22) was cloned into the intermediate vector pGEM-T-Easy, 
which contains a single 3' T overhang for cloning of DNA products, which have a single 
3' A overhang. To do this cloning it was first necessary to incorporate the 3' A overhang 
into the hICAD-L fragment containing the second TEV site. Therefore, it was incubated 
with TaKaRa LA Taq (Takara Bio Inc.). The reaction was performed at 68° C for 10 
minutes, and then the product was gel purified and cloned into pGEM-T-Easy (construct 
AA5.4). A further extension was performed in a PCR reaction with oligos Sa26 and 
Sa27 (construct AA5.5), and fragments containing the first and the second TEV sites in 
the hICAD-L protein were combined (construct AA5.6). 
3.2.9 Construction of hi CAD-L21" 
To construct hICAD-L with two PreScission protease sites (hICAD-L21 ), a 
two-step PCR reaction was used (see chapter 5.6 and Fig. 5.7). The hICAD-L fragment 
containing two PreScission protease sites (Cordingley et al., 1990; Walker et al., 1994) 
was amplified with Sa178 and Sa179 primers during the first seven cycles of the PCR 
reaction. Then the product was diluted 100 times and used as a template for the second 
PCR reaction with primers Sa181 and Sa183, which was performed during the next 
thirty cycles. The reaction was performed with TaKaRa LA Taq (Takara Bio Inc.). All 
other reaction conditions were as recommended by the manufacturer. 
3.2.10 DNA sequencing 
The BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems) was 
used for sequencing the plasmid constructs. Reactions were performed according to the 
manufacturer's instructions with 300 ng of plasmid DNA and 1.6 pM of the sequencing 
primer. The DNA sequencing reactions were analysed on the ABI 3100 sequencing 
machine by the School of Biological Sciences Sequencing Service, University of 
Edinburgh. 
3.2. 11 Isolation of total RNA and RT-PCR 
Total RNA was prepared from DT40 or HeLa cells using the TRIM reagent 
(Invitrogen). RNA isolations were performed according to the manufacturer's 
instructions. cDNA was synthesised from 5 tg of total RNA using SuperScript First—
Strand Synthesis System for RT-PCR (Invitrogen). As a negative control, no reverse 
transcriptase was added during the first-stand synthesis. The first-strand cDNA was 
amplified in a PCR reaction with TaKaRa La Taq (Takara Bio Inc.) for full-length 
cDNAs, or Taq Polymerase (Roche) for cDNA fragments. The list of primers used in the 
RT-PCR reactions is summarised in Table 3. 
Table 3. RT-PCR Drimers used in this study 
Primer name Primer sequence 	- Target cDNA Description 
mRNA length 
KS7 hCAD s same as in table 2 hCAD 1017 full-length 
KS8 hCAD a same as in table 2 hCAD 
1017/ full-length!  
307 fragment 
Sa64 hCAD RT s fw 5'-CAAGACACTCCATC hCAD 307 fragment AACCCC-3' 
KS5 hICAD S same as in table 2 hICAD-L 1 	996 	1 full-length 
KS6 hICAD a same as in table 2 hICAD-L 
996/ full-length/ 
211 fragment 
Sa61 hICAD RT s  
fw 5'-TGGTTACCAAGGAA 
hICAD-L2 211 fragment GACCCC-3'  
Sal 64 cICAD-S fw 5'-TGGAACTCTACTTAG 
RT s AGGCC-3'  cICAD-S 271 fragment 
Sal 61 cICAD-S rv 5'-TCAAC6CCTTCTCCA 
RT a GATAGGTGAG -3'  cICAD-S 271 fragment 
Sal 94 Pre RT S fw 5'-CTAGAGCITACAGTG PreScission 304 fragment TTGAC-3'  
Sal 97 Pre RI a rv 5'-GCTGAAAATCCTTGT PreScission 304 fragment CTTCC-3'  
3.3 Tissue culture 
3.3.1 Tissue culture of DT40 cells 
The chicken DT40 B cell lymphoma cell line was cultured at 39° C in RPM! 
1640 medium with L-glutamine (Invitrogen) supplemented with 10% FBS (foetal bovine 
serum) (Sigma) and 1% chicken serum (Invitrogen). To transfect DT40 cells by 
electroporation, 10 pg of DNA was added to 5-10x106 cells and electroporated (950 
microfarads, 300 V on a Bio-Rad Gene Pulser system) in OptiMEM ! medium 
(Invitrogen). The cells were then incubated for 24 hours to recover after electroporation. 
For stable integration of plasmid DNA, the transfected cells were plated into 96 well 
dishes with the drug for selection, and after 7 to 10 days, individual clones were isolated. 
The list of stable cell lines constructed is summarized in Table 4. The following 
concentrations of drugs were used for selection of stable cell lines: Puromycin 0.5 tg/m1 
(Calbiochem), Zeocin 275 pg/ml (Invitrogen), Histidinol 1 mg/mi (Sigma), and 
Hygromycin B 1.75 mg/mI (Calbiochem). Doxycycline (Dox) I jig/ml (Calbiochem) 
was added to induce the Tet-On system in the DT40 cells. 
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Table 4. The list of stable cell lines 
Stable cell line name Genotype Stably expressed Made 













CAD knockout with loxP-neo- (ICAD'47 - /AA4.3 SC4.2 
loxP cassette CAD_**) 
SC4 4 
CAD knockout with removed 
(ICAD/CAD - /AA4.19 SC4.3 
loxP-neo-loxP_cassette  
(ICAD_*/CAD '+) SC4. 1 
SC4.5 
ICAD heterozygote with loxP- and - /AA4.12 and 
puro-tk-loxP cassette (ICAD /-'/CAD-/-)  SC4.4 
ICAD heterozygote (ICAD'-/CAD- ) 
SC4.6 with removed loxP-puro-tk- and - /AA4.1 9 SC4.5 
loxPcassette (ICAD'-/CAD)  
SC4 7
ICAD knockout (lCAD/CAD+k) - IAA4.13 SC4.6 
(clones a and b)  
5C4.8 
ICAD/CAD double knockout 
(ICAD-/-/CAD-'-) -  /AA4.13 SC4.6 
(clones a and b)  
SC4.9 hCAD (ICAD-'-/CAD-'-) hCAD/AA5.10 SC4.8 
SC4. 10 hICAD-L:hCAD (ICAD'7CAD'1 
hICAD-LJAA4. 17 
SC4.9 
hCAD/AA5. 10  





hICADL2TEh/hCAD (clones a (ICAD-'-/CAD-/-) 
hlCAD-C"/AA5.6 
hCAD/AA5.10 SC5.1 




(ICAD-'-/CAD 	) hICADL2TE/AA5.6 SC5.2 
(clones a and b) hCAD/AA5.10 
rtTNAA5.1 1  
MBP-TEV/AA5.1 8 
SC5.4 MBPTevste.mTEV protease (ICAD-/-/CAD '1 h I CADL2TEh/AA5.6 SC5.1 hCAD/AA5. 10 
rtTAJAA5.1 1  
PreScission/ 
SC5 5 




(clones a, b, e) 
/AA5.26  
RE  PreScission/hlCAD-L21 
PreScission/ 
 
SC5.6 (clones c and d) 
(ICAD-4-/CAD-/-)AA5.21 SC4.8 
- /AA5.26  
SC5 ' hlCAD-L2PRE 	(clones a (ICAD--/CAD-/-) 
hICAD-L2 
/AA5.26 SC4.9 
and b) hCAD/AA5.10  
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hICAD-S2' ev, 
SC6. 1 hI CADS2TEI:  hi CAD-L: hCAD (ICAD'7CAD'1 AA6. 15 SC4.10 hICAD-LJAA4.1 7 
hCAD/AA5.1 0  
hlCADS/ AA6.14 
SC6.2 hICAD-S:hICAD-L:hCAD ([CAD-4-/CAD-'-) hICAD-LIAA4. 17 SC4. 10 
hCAD/AA5.1 0  
SC6.3 hICAD-S:hCAD (ICAD'7CAD) hICAD-S/ AA6.14 SC4.9 hCAD/AA5.1 0  
SC6.4 cICAD-S (clones a, b, c) (ICAD'7CAD) cICAD-S/AA6.8 SC4.7 
cICAD-L-3tagl 
SC6.5 cICAD-L-SATH:cCAD (lCAD/CAD'1 AA6.6 SC4.8 
cCAD/AA6.9  
CAD__* - CAD allele with blasticidin S resistance (bs) marker 
CAD-/-** - CAD allele with IoxP-neo-loxP cassette replaced for Bs resistance cassette 
lCAD1'_* - ICAD allele with loxP-puro-tk-loxP cassette 
3.3.2 Transfection of DT40 cells by nucleofection 
DT40 cells (1 xl 0) in the logarithmic growth phase were used for nucleofection. 
The cells were centrifuged at I 500xg for five minutes, then washed with PBS and 
centrifuged again at I 500xg for five minutes. The cells were resuspended in 100 tl of 
Nucleofector solution from the Cell Line Nuclefector Kit V (Amaxa Biosystems) with 
an additional 10 g of plasmid DNA. The sample was nucleofected using 
programme B23 of the Nucleofector I! (Amaxa Biosystems). After nucleofection, the 
cells were transferred to growth media. 
3.3.3 Tissue culture of HeLa cells 
HeLa cells were cultured attached in RPM! 1640 media with L-glutamine 
(Invitrogen) supplemented with 10% FBS (Sigma) at 37°C. The cells were detached 
from the flasks with 1% trypsin (!nvitrogen). 
52 
3.4 Methods for the analysis of DT40 cells 
3.4.1 Annexin V-staining 
The progress of cells into apoptosis upon treatment with 10[LM etoposide was 
assessed with the Annexin-V-FLUOS Staining Kit (Roche Applied Science, Burgess 
Hill, UK) according to the manufacturer's instructions. Annexin V-stained cells were 
diluted in PBS and analysed using a Becton Dickinson Calibur flow cytometer. The Cell 
Quest software was used for data acquisition and analysis. 
3.4.2 Living cell quantification analysis with trypan blue 
DT40 cell suspensions were mixed with an equal amount of 0.4 % trypan blue 
solution (Sigma-Aldrich). After five minutes, the mixture was transferred to the 
chambers of a hemocytometer. Cells that excluded trypan blue were scored as living. 
3.5 Targeted disruption of the Gallus gallus ICAD gene 
To construct the ICAD knockout, a phage was isolated by Dr. Kumiko Samejima 
containing an approximately 18 kb fragment of the chicken ICAD genomic region 
through screening of a X FIX II DT40 genomic library. A 9.2 kb fragment of this ICAD 
phage DNA was sequenced by Matthew A. Sims (GenBank accession number 
EF632343) and a 2.7 kb open reading frame (ORF) was identified (2614-5318 bp of the 
Gallus gallus genomic sequence), together with 2.6 kb 5' and 3.9 kb 3' non-coding 
regions (arms) flanking it. To construct the ICAD knockout, I completely removed the 
ORF using a targeting vector containing a 2.0 kb 5' arm (579-2612 bp) and a 3.4 kb 3' 
arm (5319-8710 bp) from the non-coding regions. This targeting vector was constructed 
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by PCR and direct cloning from the ICAD phage DNA into the pBluescript KS (+) 
vector. 
A selection cassette was placed between the 5' and 3' ICAD non-coding regions. 
Drug resistance cassettes flanked with loxP sites (Arakawa et al., 2001) were used in the 
targeting vector. For the first targeting, a cassette consisting of the puromycin resistance 
gene (puro) and the thymidine kinase (tk) gene flanked by mutant loxP sites (loxP-puro-
tk-loxP cassette) was used. This was constructed by cloning the Herpes simplex virus tk 
gene from the plasmid pBT/SP-TK (gift of Adrian Bird) into the loxP-puro-loxP cassette 
in the pLoxPuro vector (Arakawa et al., 2001). For the second targeting, a loxP-puro-
loxP cassette lacking tk coding sequences was used. 
The knockout constructs were linearized with restriction enzyme KpnI before 
transfection into DT40 cells. Stable cell lines were selected with puromycin. After the 
first targeting, the loxP-puro-tk-loxP cassette was removed by Cre-recombinase 
expressed from transiently transfected vector pCAGGS-Cre (Araki et al., 1995). 
Following transfection, cells were diluted and grown for six to seven days to obtain 
individual colonies without drug selection. Next, cells were replica plated in media with 
and without the drug to identify clones that had lost the marker due to the removal of the 
loxP drug resistance cassette. 
3.6 Southern Blotting 
Throughout the knockout construction procedure, each step was confirmed by 
Southern blotting. Genomic DNA from DT40 cells was isolated using Tail buffer (50 
mM Tris-HCI pH 8.8, 100 mM EDTA, 100 mM NaCl, 1% SDS) supplemented with 0.5 
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mg/ml proteinase K. The samples were mixed and incubated at 48°C for 12 hours, and 
then the mixture was shaken vigorously and 6 M NaCl was added (200 gI per 500 tl of 
Tail buffer). The products were mixed and centrifuged at 18,000 x g for 10 minutes. The 
supernatant was precipitated with an equal volume of isopropanol and washed with 70% 
ethanol. Genomic DNA (5 p.g) was digested with the restriction enzyme BglII for 24 
hours, then separated on a 0.8% agarose gel. The gel was then processed, and the DNA 
was transferred to Hybond N nylon membrane (Amersham). DNA hybridizations were 
performed at 65° C in phosphate buffer (0.5 M Na2HPO4INaH2PO4 pH 7.2, 7% SDS) 
using an external 5'-probe. Following this, the membrane was washed with phosphate 
wash buffer (0.04 M Na2HPO4JNaH2PO4 pH 7.2, 1% SDS) at 65° C two or three times 
for five minutes each. 
The 5' ICAD genomic DNA probe (0.5 kb) corresponding to the nucleotides 
1-499 of the chicken genomic sequence was amplified in a PCR reaction with KS 13 and 
KS 14 primers from the ICAD phage DNA (construct AA4.5). The 3' ICAD genomic 
DNA probe (0.5 kb) corresponding to the nucleotides 8711-9210 of the chicken genomic 
sequence was amplified in a PCR reaction with KSI5 and KSI6 primers. The probes 
were labelled with 32P (Amersham) using the Megaprime DNA labelling system 
(Amersham). 
3.7 DNA fragmentation and DNA condensation assay 
DT40 cells were grown to a concentration of 5 x 105/ml prior to the addition of 
etoposide (10 j.tM) to induce apoptosis. Aliquots of cells were harvested at zero, two and 
four hours, then used either to isolate genomic DNA or for microscopy analysis. To 
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isolate genomic DNA, cells (2.5 x 106)  were disrupted in lysis buffer (500 mIvI Tris-HC1 
pH 8.0, 2 mM EDTA, 10 mM NaCl, 1% SDS) and incubated with proteinase K 
(1 mg/ml) overnight at 48° C. The DNA was extracted with phenol, precipitated with 
ethanol, resuspended in TE buffer with RNAse A (20 .tg/ml), and analysed by gel 
electrophoresis. In addition, cells from the apoptosis reaction were analysed by 
fluorescence microscopy. DT40 cells were centrifuged at 63 x g for five minutes onto 
polylysine-coated microscope slides (BDH Laboratory Supplies) using a Cytospin 3 
cytocentrifuge (Shandon). The cells were fixed for five minutes with 4% formaldehyde 
(Electron Microscopy Sciences) in PBS, washed in PBS, and stained with 1.5 jig/ml 
4',6-diamidino-2-phenylindole (DAPI). 
3.8 Fluorescence microscopy 
Microscopy was performed using a DeltaVision system (Applied Precision, 
Issaquah, WA) based on an Olympus [X-70 with a Chroma Technology Sedat filter set, 
driven by the SoftWorx software under standard conditions. Images were deconvolved 
using the standard Soft Worx deconvolution algorithm. 
3.9 SDS-PAGE and Immunoblotting 
Protein samples were harvested from DT40 cells and resuspended in PBS at a 
concentration of 1-1.5 x 105  cell equivalents/jil. The samples were sonicated on ice once 
for 15 seconds using a MSE Soniprep 150 sonifier (Sanyo). Next, 3x SDS Gel-loading 
buffer (150 mM Tris-HCI pH 6.8; 6% SDS; 0.3% bromophenol blue; 30% glycerol; 300 
mM DYE) was added and samples were heated for 6 to 10 minutes (depending on the 
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sample volume) at 1000  C. SDS-PAGE was carried out using the Tris-glycine buffer 
system (Sambrook and Russell, 2001). 
After separation by SDS-PAGE, proteins were transferred by electroblotting to 
nitrocellulose membranes (Amersham) using transfer buffer (25 mM Tris base; 0.2 M 
glycine; 0.1% SDS, 20% methanol). Transfers were performed at 220 mAmp for 140 
minutes at 4° C. The membranes were rinsed with PBS for one minute, incubated for one 
hour in a blocking buffer (PBS; 5% milk; 0.05% Tween 20), and then incubated with the 
primary antibody in PBS supplemented with 1% milk and 0.05% Tween-20. After 
incubation, the membranes were washed three times for five minutes in the same 
solution and incubated with the secondary antibody. The membranes were then washed 
three times for five minutes in PBS with 0.05% Tween-20. The secondary antibody was 
visualised using ECL Western Blotting Detection reagents (Amersham). 
Table 5. Antibodies used for immunoblottina (IB' and immunofluorescence (IF) 
Antibody against species Source dilution IB/ dilution IF/ 
incubation time incubation time 
human ICAD N-terminal rabbit Sigma-Aldrich 1:500/ not 
over 12 hours determined 
at 40C 
human ICAD C-terminal rabbit Sigma-Aldrich 1:1000/ not 
over 12 hours determined 
at 4"C  
Myc mouse Cell Signalling 1:1000/ not 
over 12 hours determined 
at 40C 
a-tubulin clone B512 mouse Sigma-Aldrich 1:4000/ not 
1 hour determined 
at room temp. 
MBP rabbit NEB 1:2000/ not 
3 hours determined 






SBP mouse Mayo Clinic not 1:100/ 
Monoclonal determined 30 minutes 
antibody core at 37°C 
facility  
anti-rabbit, HAP donkey Amersham 1:10000/ not 
conjugated  1 hour determined 
at_  room _temp.  
anti-mouse, HAP Sheep Amersham 1:10000/ not 
conjugated 1 hour determined 
at_  room _temp.  
anti-mouse, FITC Goat Jackson not 1:200/ 
conjugated Laboratories determined 30 minutes 
at 37°C 
3.10 Indirect immunofluorescence microscopy with anti-SBP 
monoclonal antibody 
DT40 cells were centrifuged at 63 x g for five minutes onto polylysine-coated 
microscope slides (BDH Laboratory Supplies) using the Cytospin 3 cytocentrifuge 
(Shandon). The slides were then fixed for five minutes with 4% formaldehyde (Electron 
Microscopy Sciences) in PBS, washed with PBS for five minutes, then washed three 
times (one minute each) with 1 x TEEN buffer (1 mM Triethanolamine:HC1 pH 8.5; 0.2 
mM NaEDTA; 25 mM NaCl) supplemented with 0.1% Triton X-100 and 0.1% BSA. 
Anti-SBP monoclonal antibody was added in the TEEN buffer and incubated for 30 
minutes at 37° C. After incubation, the slides were washed three times (two minutes, five 
minutes, and three minutes) with I x KB buffer (10 mM Tris:HCI pH 7.7; 0.15 M NaCl; 
0.1 % BSA), then incubated with secondary mouse-FITC antibody (Jackson 
Laboratories) in KB buffer for 30 minutes at 37° C. Slides were then washed three times 
(two minutes, five minutes, and three minutes) with I x KB buffer, stained with DAPI 
(Vector Laboratories), and analysed using the DeltaVision system. 
3.11 Assay for CAD activation in vitro 
Cytosolic extracts were prepared from DT40 cell lines in exponential growth. 
The cells were washed once in PBS and then with KPM buffer (50 mM pipes pH 7.0, 50 
mM KC1, 5 mM EGTA, 2 mM M902, 1 mM dithiothreitol). No protease inhibitors were 
added. The pellet was lysed by three cycles of freezing and thawing and subsequent 
sonication, then centrifuged at 55,000 x g for 30 minutes at 4°C. Each reaction used 75 
pg of supernatant extract protein per 2 jtg of plasmid DNA in CAD buffer (10 mM 
HEPES pH 7.4, 50 mM NaCl, 5 mM EGTA pH 8.0, 2 mM MgCl2, 1 mM dithiothreitol) 
plus an ATP regenerating system (Wood and Earnshaw, 1990). Caspase-3 (200 U, 
Calbiochem) or TEV protease (20 U, Invitrogen) was added to the reaction mixture 
containing cell extract and plasmid DNA. After incubation for two hours at 37° C the 
reaction was terminated by isolating of the plasmid DNA by phenol extraction. The 
extracted DNA was then electophoresed on a 1.5% agarose gel. 
TEV protease buffer (50 mM Tris-HC1, pH 8.0, 0.5 mM EDTA, 1 mM DTT) was 
used for quick assesement of hICADL2T'  cleavage by TEV protease according to the 
manufacturer instructions. In this case, no plasmid DNA was added. 
59 
4. Constructing and characterizing ICAD 
and ICAD/CAD double knockouts 
in DT40 cells 
MOO 
4.1 Introduction 
CAD is the main nuclease involved in apoptotic DNA fragmentation, while 
ICAD is its inhibitor and compulsory chaperone. It may be hypothesised that CAD can 
kill the cell once artificially dissociated from its inhibitor ICAD. This, however, can 
only be the case if there are no other proteins preventing CAD activation in vivo and if 
CAD can efficiently access the DNA upon its activation. Importantly, some proteins 
such as nucleophosminl1323 (Ahn et al., 2005) and CIIA (Cho et al., 2003) have been 
suggested as potential CAD inhibitors. Therefore, one of the primary aims of my thesis 
was to activate CAD in vivo and to identify whether any constrains other than ICAD can 
interfere with this activation. This would allow research to shift from exploring the 
fundamental nature of the ICAD and CAD proteins to investigating their practical 
application based on the hypothesis that CAD as a nuclease can kill the cell and that 
such a property can be potentially useful in killing cancer cells. 
To identify CAD role in cell death, it was necessary to construct a model system, 
to be described in Chapter 5. It was, however, first necessary to isolate an ICAD/CAD 
double knockout in DT40 cells, which are a part of the model system design. Also, in 
another project, the ICAD null background was used to test the function of ICAD-S and 
ICAD-L splice forms in vivo, either separately or together, in the absence of interference 
from the endogenous ICAD splice forms, as described in Chapter 6. 
The current chapter is focused on the construction and characterisation of the 
ICAD and ICAD/CAD double knockouts in DT40 cells. The DT40 cell line was used 
because it is characterised by a high frequency of homologous recombination (Winding 
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and Berchtold, 2001). The two main features of CAD are its ability to form 
internucleosomal DNA fragmentation (Enari et al., 1998; Halenbeck et al., 1998; Liu et 
al., 1998; Liu et al., 1997; Sakahira et al., 1998) and stage II chromatin condensation 
(Samejima et al., 2001). Therefore, the ICAD and ICAD/CAD double knockouts were 
assessed for their phenotype in the absence of ICAD and CAD. 
4.2 Removal of the puromycin resistance marker from the CAD 
knockout DT40 cell line 
To construct an ICAD/CAD double knockout based on the CAD knockout in 
DT40 cells (Samejima et al., 2001), it was first necessary to modify a selection marker 
set of the CAD knockout cell line. The DT40 CAD knockout cell line (Tab. 4) obtained 
previously (Samejima et al., 2001) contained a blasticidin S resistance (bs) marker in 
place of one allele and a puromycin (puro) resistance marker in place of the second 
allele of the CAD gene (Fig. 4.1 A). As the puro resistance marker has been proven to be 
highly effective in the selection of homologous recombinants in the DT40 cell line in 
Professor Earnshaw's lab, it was decided to remove this marker to allow its future use in 
the ICAD targeting vector for the construction of the ICAD knockout. Drug resistance 
cassettes flanked by mutant !oxP sites were used for targeting and recycling (Arakawa et 
al., 2001). 
A CAD targeting vector with a neomycin resistance cassette flanked by mutant 
loxP sites (construct AA4.3) was prepared from the CAD targeting vector made 
previously by Dr. Kumiko Samejima. This new CAD targeting vector was transfected 
into the chicken DT40 CAD knockout cell line (SC4.2) and four CAD knockout clones 
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(SC4.3) with the integrated loxP-neo-loxP cassette instead of the puro resistance marker 
were selected by resistance to Neomycin and sensitivity to Puromycin (Tab. 4). Isolated 
clones were analysed by Southern blotting to confirm the targeted removal of the puro 
resistance marker (Fig. 4.IB lanes 2- 
5). The targeting efficiency was 
XhoI t1_O 
____ 14.3%. allele I 
5 pro  Puro 
5' CAD arm 3' CAD arm 
Xhol 13.6 kb Xhol 	Fig. 	4.1. 	Replacement 	of 	puro 
allele 2 
bs resistance cassette for loxP-neo-loxP 
+ cassette 	in 	CAD 	knockout 	cells. 
XhoI k XhoI (A) Diagram of the two CAD alleles, 
allele i which 	have puro and 	bs 	resistance iOxP 	IoxP 
neo markers. The puro resistance cassette 
AM 13.6 kb XhoI 
10 	was replaced with a neo 	resistance 
allele2 
bS iJL' cassette flanked by mutant loxP sites. 
B neolbs 
The CAD 5' radioactive probe is located 
puro/bs 	a b 	c 	d outside 	the 	targeting 	vector. 	(B) 
kb 	Southern Blot. Genomic DNA was 
23.1 




















a b c d e neo/bs 
(2 
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To recycle the loxP-neo-loxP cassette (Fig. 4.2A) from the CAD knockout cell 
line (SC4.3 clone c), it was transiently transfected with a pCAGGS-Cre vector (Araki et 
al., 1995) containing the gene coding Cre recombinase. The clones picked up after the 
transfection were tested for the resistance to Neomycin by replica plating, and those that 
died after the addition of Neomycin were isolated (SC4.4). The removal of the neo 
resistance cassette with mutant IoxP sites by Cre recombinase was confirmed by 
Southern blotting (Fig. 4.2B lanes 1-5). The efficiency of removal was 3.5%. 




Xhol 	 13.6 kb 	 XhoI 







13.6 kb 	 XhoI 
ellele2 
bs 	 1 kb 
Fig. 4.2. Removal of loxP-neo-loxP 
cassette 	by 	Cre-recombinase. 
(A) Diagram of the loxP-neo-loxP 
cassette removal from the CAD genomic 
region. The CAD genomic locus 
contained bs resistance and neo 
resistance cassettes in two alleles. The 
loxP-neo-loxP cassette was removed by 
transient transfection with vector encoding 
Cre-recombinase. (B) Southern Blot. 










4.3 Construction of ICAD and ICAD/CAD double knockouts in DT40 
cells 
To construct the ICAD knockout a phage DNA containing a fragment of the 
chicken ICAD genomic region was isolated by Dr Kumiko Samejima (GenBank 
accession number EF632343). In this fragment a 2.7 kb ORF was identified encoding 
chicken ICAD (Fig. 4.3). ICAD knockout strategy results in complete removal of its 
ORF. This allowed me to study the function of ICAD-L and ICAD-S separately after 
their reintroduction into a knockout background in which no fragment of endogenous 
ICAD protein could be produced. 
To delete the ICAD ORF, I constructed a targeting vector containing the 5' and 
3' noncoding regions of ICAD but lacking the coding region. A selection cassette (loxP-
puro-tk-loxP) was inserted between these non coding regions. A puromycin resistance 
gene was used for the positive selection of homologous recombinants. The cassette was 
flanked by mutant loxP sites to allow its removal by Cre-recombinase (Arakawa et al., 
2001). The removal of the cassette allows marker recycling so that only a single 
knockout vector was required to disrupt both alleles. During removal of the cassette by 
Cre recombinase, two mutant loxP sites are joined to form a single non-functional site 
that does not interfere with the subsequent use of Cre-recombinase. 
I originally planned to use the thymidine kinase (tk) gene for negative selection 
to detect cassette removal by Cre-recombinase. Such negative selection is achieved 
when thymidine kinase activates the pro-drug ganciclovir by phosphorylation (Cannon 
et al., 1999). As a result, clones could be selected in which the ICAD' knockout 
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occurred and then subsequently in which the puromycin resistance marker had been 
removed by Cre recombinase. 
I) Construction of the ICAD targeting vector 
5' arm ioxP 	puro-tk 	loxP 3' arm 
!MM 2.1 kb 	ICAD ORF 	 kb 
Bqlll 	 Start Bfll Stop Sphl 	BgIIl 
	
5.3 kb 	 - 	 7.1 kb 
Sphl 
Ii) ICAD first targeting 
Bfll 	 loxP 	puro-tk 	 Sphl 	BgIll 
15.5 kb 	 5X—kb 
Ill) Removal of resistance cassette from ICAD heterozygote 
Bgfll 	 Sphl 	 Sphl 	BgIli 
<11.0kb 	 I < 
5.4 kb 
IV) ICAD second targeting (knockout) 
loxP puro  loxPSphl 	 Sphl 
I kb 
Fig. 4.3. Structure and targeting of the Gal/us gallus ICAD gene. DT40 ICAD gene and the 
targeting strategy using a targeting vector with a resistance cassette flanked by ICAD 5' and 3' 
noncoding genomic regions. The location of 5' and 3' external radioactive probes for Southern 
Blot analysis is shown. The DNA fragments, which are formed after restriction digest with BgAI 
and Sphl enzymes and recognized by radioactive probes, are shown with arrows. 
The ICAD targeting vector (Fig. 4.3) with the loxP-puro-tk-loxP cassette 
(construct AA4.12) was used to transfect DT40 wild type cells and also DT40 cells with 
a complete deletion of the CAD gene (Tab. 4). After transfection, clones (SC4.5) were 
isolated using puro as a selectable marker. Correct targeting was recognized by Southern 
Blot analysis with a 5'-external probe, using BglII digested genomic DNA (Fig. 4.4A). 
The probe recognized a 5.3 kb band corresponding to a DNA fragment from the intact 
ICAD allele (Fig. 4.4A lanes 1-2) plus a 15.5 kb band corresponding to the integrated 
MO 
loxP-puro-tk-loxP cassette (Fig. 4.4A lanes 3-4). The correct integration was further 
verified with an ICAD 3'-external probe (Fig. 4.413). As a result, heterozygous clones 
with the genotype ICAD'/CAD' and ICAD'/CAD' were isolated (the * indicates 
alleles containing the tk gene). The total targeting efficiency of homologous 
recombination was 32% for isolating these ICAD' heterozygotes. 
The use of thymidine kinase as a negative selection marker in DT40 was tested 
in cell lines containing the integrated ICAD targeting vector bearing the thymidine 
kinase gene. However, DT40 cells expressing HSV thymidine kinase demonstrated 
significant resistance to death in medium containing ganciclovir. Ganciclovir could 
block the growth of these cells over a wide range of concentrations (0.015 - 32 tM). 
However, after 10-14 days the cells incubated with 0.015 - 4 j.tM ganciclovir started to 
grow again, indicating that the drug had failed to kill the cells. The use of drug 
concentrations higher than 4 iM interfered with the growth rate of DT40 cells even 
without the exogenous thymidine kinase gene (data not shown). Therefore, ganciclovir 
appears not to be useful for negative selection in DT40 cells. 
To remove the loxP-puro-tk-loxP cassette, ICAD"/_*ICAD and 
ICAD'/CA1X' clones were transiently transfected with vector pCAGGS-Cre 
expressing Cre-recombinase. After transfection, the cells were grown without drug 
selection, diluted to obtain individual colonies, and then tested for their sensitivity to 
Puromycin by replica plating. Clones (SC4.6) in which removal of the 
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Fig. 4.4. Southern Blot analysis of genomic DNA prepared from the following: ICAD' (lanes 1-
2); ICAD_*  (ICAD heterozygote with puromycin/tk marker -lanes 3-4); ICAD' (ICAD 
heterozygote with puromycin/tk marker excised - lanes 5-6); and ICAD' (lanes 7-8). Genomic 
DNA (5 jig) was digested by 8gM. The radioactive 5' probe was located outside of the targeting 
vector. The figure shows data from two independent ICAD clones (lanes 7a and 7b) and two 
independent ICAD17CAU' clones (lanes 8a and 8b). (A) The genomic DNA was digested with 
BgIll and analysed with 5' external radioactive probe. (B) The DNA was digested with Sphl and 
detected with 3' external radioactive probe. 
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These clones were further tested by Southern Blotting (Fig. 4.4A). The 5'-external probe 
recognized the shift from 15.5 kb to 11.0 kb that occurred as a result of the removal of 
the 4.5 kb loxP-puro-tk-loxP cassette (Fig. 4.4A lanes 5-6). As a result, clones with the 
genotype ICAD /CAD' and ICAD/CADwere isolated. The removal efficiency of 
the loxP-puro-tk-loxP cassette was 11 %, so lack of the tk selection did not prove to be a 
significant impediment. 
Once the puromycin marker had been removed from the ICAD' heterozygotes, 
it was possible to use the ICAD targeting vector to target the second ICAD allele. An 
ICAD targeting vector with a loxP-puro-loxP cassette (construct AA4. 13) was used for 
this second targeting. The resulting drug-resistent clones were checked by Southern 
blotting (Fig. 4.4A). The 5'-external probe recognized the disappearance of the 5.3 kb 
band corresponding to the intact ICAD allele and appearance of the 13.5 kb band 
corresponding to the fragment bearing the integrated loxP-puro-loxP cassette (Fig. 4.4A 
lanes 7-8). The targeting efficiency for the second ICAD allele was 11%. The proper 
integration of the targeting vector by homologous recombination was confirmed for two 
clones SC4.7 (a and b) with a single ICAD' knockout (ICAD/CAD)(Fig. 4.4A lanes 
7a-7b) and two clones SC4.8 (a and b) with the JCAD'7CAD' double knockout (Fig. 
4.4A lanes 8a-8b). 
4.4. The pattern of apoptosis induction in ICAD and ICAD/CAD 
double knockouts 
To determine whether apoptosis proceeds normally in the ICAD' and ICAD-/- LY' 
/CAD 4 D' double knockout cell lines, both were tested for the presence of 
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phosphatidylserine on the outer surface of the plasma membrane following treatment 
with etoposide. Exposure of phosphatidylserine on the outer leaflet of the plasma 
membrane reflects the loss of membrane asymmetry that occurs during apoptotic 
execution (Fadok et al., 1992), and can be detected using the binding of Annexin V 
(Koopman et al., 1994). 
The percentage of Annexin V-positive cells was tested in the wt, ICAD' and 
ICAD 17CAD' double knockouts after the induction of apoptosis with etoposide (Fig. 
4.5). There was a small background amount of Annexin V positive cells at 0 time in all 
of the cell lines. The number of Annexin V-positive cells increased dramatically at 2 
hours after apoptosis was induced by etoposide, with nearly half of the cells becoming 
apoptotic at this point. By 4 hours most of the cells were Annexin V-positive, with only 
minimal changes in the cultures thereafter. No difference in the kinetics of 
phosphatidylserine exposure was observed between the wild-type, ICAD' and ICAD-1-
CAD-1- 
'
' cells, indicating that deletion of the ICAD gene, either singly or in combination 
with CAD has no effect on the kinetics of cell death induction by etoposide in DT40 
cells. In preliminary experiments the cell death rate measured by trypan blue exclusion 
appeared to be lower in ICAD and ICAD/CAD double knockouts (data not shown). 
That is consistent with another study in which mouse thymocytes lacking DFF45/ICAD-
L were reported to be more resistant to several proapoptotic stimuli (Boulares et al., 
2001; Thomas et al., 2000; Zhang et al., 1999)and suggests that CAD accelerates cellular 
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Fig. 4.5. Quantification of phosphatidylserine 
exposure on the outer leaflet of the plasma 
membrane of DT40 cells by Annexin V staining. 
This analysis was carried out for DT40 wt, ICAD 
and ICAD7CAtY' double knockout cell lines 
upon induction of apoptosis with 10 pM 
etoposide. Samples were collected at 0, 2, 4 and 
6 hours, stained with Annexin-V-FLUOS and 
analysed by flow cytometry. The number of 
Annexin V positive cells is indicated as a 
percentage of the total. (A) Annexin V staining 
for ICAD-1- knockout clones a and b. (B) Annexin 
V staining for ICAD'7CAD' double knockout 
clones a and b. The same DT40 wt data are 
shown in both panels. 	Experiments were 
repeated at least three times. The standard 
deviation is indicated by error bars. 
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4.5. Oligonucleosomal DNA fragmentation and stage II DNA 
condensation are absent in DT40 knockout cells lacking ICAD or ICAD 
plus CAD 
Oligonucleosomal DNA fragmentation was undetectable in the ICAD' knockout 
and ICAD'7CAD' double knockout cells upon induction of apoptosis with etoposide 
(Fig. 4.6A lanes 4-15). In contrast, DNA fragmentation proceeded efficiently in wild 
type DT40 cells (Fig. 4.6A lanes 1-3). The CAD' knockout had previously been 
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Fig. 4.6. DNA fragmentation and stage II chromatin condensation are absent in ICAD and 
ICAD/CAD double knockouts following induction of apoptosis by 10 pM etoposide. (A) DNA 
fragmentation. Genomic DNA samples were collected at 0, 2 and 4 hours. Two ICAD 
knockout clones (a - lanes 4-6) and (b - lanes 7-9) and two ICAD -ICAD double knockout 
clones (a - lanes 10-12) and (b - lanes 13-15) were analysed. The stable cell line expressing 
hICAD-L:hCAD (lanes 16-18) was constructed by introduction of the human cDNAs into the 
ICAU'7CAD double knockout. (B) Images of cells before (0 hour) and after (4 hours) induction 
of apoptosis. DNA was stained with DAPI. The percentage of cells with normal, stage I and 
stage II chromatin condensation is indicated. Data represent a minimum of at least three 
independent experiments with over 300 cells counted for each. 
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The absence of oligonucleosomal DNA fragmentation in the ICAD knockout indicates 
that ICAD protein is absolutely required as a chaperone for synthesis of active CAD in 
DT40 cells. This is consistent with results obtained in certain cells from ICAD knockout 
mice (Zhang et al., 1998). 
Chromatin condensation was also affected in ICAD-1- knockout and 
ICAD 17CAD' double knockout cells (Fig. 4.613). Stage II chromatin condensation was 
absent in both knockout cell lines upon induction of apoptosis. Only peripheral (stage I) 
chromatin condensation was observed. There were no significant differences in the 
pattern of DNA condensation in ICAD' knockout and ICAD-1-ICAD-1- double knockout 
cells, both of which resembled the DT40 CAD' knockout, characterized previously 
(Samejima et al., 2001). The induction of apoptosis with etoposide for longer than 4 
hours did not result in DNA fragmentation or stage II chromatin condensation in any of 
these knockout cell lines (data not shown). Therefore, CAD nuclease is required for 
stage II DNA condensation in DT40 cells, and stage I DNA condensation must be driven 
by another mechanism. 
Interestingly, the phenotype of stage I chromatin condensation in the knockout 
cells differed slightly from the stage I condensation that is observed normally as the first 
step in apoptotic chromatin condensation (Fig. 4.613). In the ICAD', CAD' and ICAD-1- ' 
ICAD" ' knockout cell lines, terminal stage I condensed chromatin resembled small round 
balls distributed around the nuclear periphery. In contrast, stage I condensed chromatin 
in cells undergoing apoptotic chromatin condensation frequently resembles a smooth 
line of compact chromatin around the nuclear periphery. 
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4.6. Human ICAD and CAD proteins can rescue the DNA 
fragmentation phenotype of DT40 ICAD/CAD cells. 
To test whether ICAD/CAD function as an independent module for chromatin 
processing in apoptosis I used the ICAD-1-ICAD-1- double knockout cells to construct 
humanized DT40 cell lines expressing human ICAD and CAD (Tab. 4). DNA 
fragmentation and stage II chromatin condensation upon induction of apoptosis were 
completely rescued in ICAD-1-ICAD-1- double knockout cell lines (SC4.10) expressing 
hICAD-L and hCAD (Fig. 4.6A lines 16-18 and Fig. 4.6B). This humanized cell line 
provided the basis for our further studies of the role of ICAD-S in CAD regulation. 
74 
4.7 Discussion 
ICAD/DFF45 and CADJDFF40/CPAN together compromise a module that is 
responsible for the destruction of cellular DNA during classical apoptosis (Enari et al., 
1998; Halenbeck et al., 1998; Liu et al., 1998; Liu et al., 1997; Sakahira et al., 1998). 
This module has been widely studied, but several key questions remain, such as the role 
of the ICAD splice variant ICAD-S in vivo, the role of other nucleases, such as 
endonuclease G, in DNA cleavage during apoptosis and the role of other molecules, 
including nucleophosminl1323 and CIJA, as 'back-up' inhibitors of CAD in vivo. To 
address these questions, I constructed a humanized system in which the ICAD and CAD 
genes of chicken DT40 cells were deleted and the function of the ICAD/CAD module 
restored by the expression of wild type and variant forms of human ICAD and CAD. 
Chicken DT40 cells lacking ICAD, CAD or both are deficient in DNA 
degradation and in the formation of apoptotic bodies during etoposide-induced 
apoptosis, but the other aspects of apoptosis appear to proceed with normal kinetics, as 
shown previously in DT40 CAD' (Samejima et al., 2001), mouse ICAD' (Zhang et al., 
1999) and mouse CAD' knockouts (Kawane et al., 2003). In DT40 cells, chromatin 
condensation is arrested at stage I, with the condensed chromatin appearing as a 
necklace of small beads around the nuclear periphery. These results confirm that CAD 
activity is required for full apoptotic chromatin condensation (Samejima et al., 2001). It 
is possible that cleavage by CAD releases the DNA from local entanglements or 
associations with nuclear substructures that constrain the condensed DNA into bead-like 
domains in the absence of CAD activity. Interestingly, whatever these constraints must 
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be, they are located around the nuclear periphery, as even in the absence of CAD 
activity, no condensed DNA is detectible in the interior of apoptotic DT40 cell nuclei. 
The formation of small, round ball structures in cells with absent CAD may be a 
specific feature of the factor responsible for the chromatin condensation up to stage I. 
AIF can contribute to chromatin condensation (Susin et al., 2000; Susin et al., 1999) and, 
therefore, could be responsible for the stage I phenotype in the cells with absent CAD. 
This hypothesis can also be supported by the fact the AIF is able to physically interact 
with DNA and to condense it in vitro (Vahsen et al., 2006). Moreover, AIF co-localizes 
with DNA during apoptosis (Ye et al., 2002). Such co-localisation is particularly evident 
during stage I chromatin condensation (Ye et al., 2002). In cells expressing the caspase-
resistant ICAD mutant to prevent CAD activation, the depletion of A1F by RNAi or 
blocking antibody affected the phenotype of stage .1 chromatin condensation (Yuste et 
al., 2005), yet some chromatin condensation was still observed. Topoisomerase lict can 
also contribute to chromatin condensation in HeLa nuclei (Durrieu et al., 2000). Its 
function in chromatin condensation during the induction of apoptosis with etoposide in 
DT40 cells may not be seen because etoposide is also a topoisomerase Ha inhibitor. The 
exact role of AIF, topoisomerase ha or other factors possibly involved in stage I 
chromatin condensation remains to be tested. 
DNA fragmentation was absent in the ICAD and ICAD/CAD double knockout 
after the induction of apoptosis. This data is consistent with the previous findings from 
the DT40 CAD knockout (Samejima et al., 2001), meaning that the phenotype is similar 
when either ICAD or CAD is absent. Endonuclease G could cause the oligonucleosomal 
DNA fragmentation in mouse fibroblasts (Li et al., 2001); for an alternative view, see 
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(Irvine et al., 2005). However, Endonuclease G does not appear to work in DT40 cells. 
Also, there are no other nucleases, for example, DNAseI (Oliveri et al., 2001) or 
DNAseII (Kawane et al., 2003), that can cause DNA fragmentation in DT40 cells if 
activated by the etoposide treatment. This, however, still does not exclude the possibility 
that some other protein with nuclease activity could be activated in DT40 by alternative 
apoptotic stimuli. 
In addition, as part of my thesis research, the methodology for the recycling of 
drug resistance cassettes with mutant loxP sites by the transient transfection with Cre-
recombinase was optimised for application in DT40 cells. Mutant loxP sites have been 
previously used in mouse embryonic stem cells and DT40 cells (Arakawa et al., 2001; 
Araki et al., 1997; Kanayama et al., 2005). The recycling of the loxP tagged sequences 
in DT40 cells, however, was achieved using MerCreMer, which is an N-terminal and C-
terminal fusion of Cre-recombinase with Mer (mutated estrogen receptor) (Verrou et al., 
1999). The drawback of this method is that it requires the establishment of a stable cell 
line expressing MerCreMer (Arakawa et al., 2001). Therefore, I decided to optimise the 
method used for transient transfection with Cre-recombinase in mouse fertilized eggs 
(Araki et al., 1995) for application in DT40 cells. The efficiency of the loxP cassette 
removal without any selection was within the range of 3.5-11%. This variability may be 
due to the transient transfection efficiency. The advantage of transient transfection is that 
it allows the isolation of stable cell lines expressing MerCreMer to be bypassed, 
therefore saving time and one of the valuable selection markers. 
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5. CAD role in cell death and 
a new technology for targeted 
protein cleavage in vivo 
5.1 Introduction 
The hypothesis that activation of CAD on its own can cause cell death makes this 
nuclease an attractive target for cancer therapy. I have therefore established a model 
system in DT40 cells to test the role of CAD in cell death (Fig. 5.1). To activate CAD 
artificially in vivo in the absence of apoptosis in order to show whether this is sufficient 
to kill cells, ICAD must be destroyed. ICAD, however, in addition to its inhibitor 
function for CAD, also performs a chaperone function during translation that is 
absolutely necessary for CAD to achieve an active conformation (Enari et al., 1998). 
Therefore, the destruction of ICAD must be initiated in living cells that have already 
made CAD protein in the presence of active ICAD. To target ICAD for destruction, the 
protein must somehow be modified to make it susceptible to an artificial signal for its 
destruction. This must be done in a cell line with knockouts of the endogenous ICAD 
and CAD genes to prevent the interference of the endogenous proteins with the newly 
introduced CAD and modified ICAD genes. Site-specific proteases have been 
considered for destruction of artificially engineered ICAD protein with recognition sites 
for specific protease. 
Proteolytic enzymes have a wide range of specificities of target protein cleavage. 
The ones which are site-specific can either be involved in physiological processes in an 
organism or perform a function during viral infection (Babe and Craik, 1997; Krausslich 
and Wimmer, 1988; Seidah and Chretien, 1997). Among physiological site-specific 
enzymes used for proteolysis in vitro are activated blood coagulation factor X (Nagai 
and Thogersen, 1984), a-thrombin (Chang, 1985) and enterokinase (LaVallie et al., 
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1993). However, all these proteases have also been reported to cleave unspecifically 
(Choi et al., 2001; Jenny et al., 2003), in part due to their short recognition sequences, 
which are five amino acids or less. The shorter the cleavage recognition site, the greater 





Cleavage of regulator, 













Fig. 5.1. Model system to test whether CAD activation can kill the cell. Apoptotic stimuli cause 
the activation of multiple pathways leading to cell death through cleavage of regulator, structural 
and repair proteins. The model system has been designed to test if one of such pathways 
involves CAD nuclease. ICAD protein was artificially engineered to incorporate either two TEV or 
two PreScission protease recognition sites instead of two caspase-3 sites. TEV protease or 
PreScission protease, under the control of inducible system in DT40 ICAD/CAD double 
knockout, can be used to initiate the cleavage of ICAD protein containing protease recognition 
sites. That would identify whether specific activation of CAD caused by cleavage of its inhibitor 
can cause cell death in the absence of apoptotic stimuli. 
By contrast, several viral proteases are characterised by stringent sequence specificity 
(Babe and Craik, 1997). A wide range of viruses can use proteases to enable specific 
post-translational modifications of their polyprotein products (Krausslich and Wimmer, 
1988). At present, TEV (tobacco etch virus) from Invitrogen and PreScission (GE 
Healthcare) are the only well characterized commercially available site-specific 
proteases with stringent specificity for their recognition site. TEV and PreScission 
proteases recognise seven and eight amino acid sites, respectively (Carrington and 
Dougherty, 1988; Walker et al., 1994). However, both of these enzymes can still cleave 
their recognition sequences in the presence of certain amino acid variations at some 
positions within the recognition sequence. TEV and PreScission proteases are 
extensively used for site-specific protein cleavage in vitro (Parks et al., 1994; Walker et 
al., 1994). In addition, TEV protease was reported to work in vivo in E. coli (Ehrmann et 
al., 1997; Mondigler and Ehrmann, 1996) and yeast cells (Smith and Kohorn, 1991; 
Uhlmann et al., 2000; Yang et al., 2005). There is, however, no published application of 
any protease for site-specific protein cleavage in vertebrate cells, as far as I am aware. 
Therefore, one of the aims of my PhD project was to develop a novel technology for 
site-specific protein cleavage in vivo. 
5.2 Introduction of TEV protease cleavage sites into human ICAD-L 
TEV protease was isolated from a plant pathogen, tobacco etch virus (Carrington 
and Dougherty, 1987). Mutational analysis identified the seven amino acid sites (Fig. 
5.2) efficiently recognized by TEV protease (Carrington et al., 1988; Carrington and 
Dougherty, 1988). To test the application of TEV protease cleavage in DT40 cells, 
hICAD-L protein was artificially modified to introduce two TEV protease cleavage sites 
in place of the two caspase-3 cleavage sites whose cleavage releases active CAD in 
apoptosis (Fig. 5.2). 
hICAD-L First site 
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Fig. 5.2. Strategy for replacement of two caspase-3 sites in hICAD-L protein with two TEV 
protease sites. Caspase-3 has two four amino acid recognition sites in hICAD-L. These sites 
were replaced by two seven amino acid TEV protease recognition sites. For the first caspase-3 
recognition site, a double stranded DNA fragment encoding the TEV protease recognition site 
was synthesized using Kienow polymerase from two long DNA oligos and then introduced into 
the hICAD-L cDNA by replacement cloning. A similar approach for the second TEV recognition 
site yielded only a partial fragment. The desired fragment was obtained by extension using PCR 
with a long primer, then introduced into the hICAD-L cDNA by replacement cloning. 
First, ICAD-L protein was modified by site-directed mutagenesis to introduce an 
EcoRV site, which allowed replacement cloning (construct AA5.1). The mutation did 
not result in any change of the hICAD-L amino acid sequence. Next, the first TEV site 
was synthesized using long primers and introduced into hICAD-L by replacement 
cloning (construct AA5.2). Then, the second TEV protease cleavage site was 
synthesized using a similar strategy (construct AA5.4). However, the insertion fragment 
for the second TEV protease cleavage site was longer than the first one (Fig. 5.2), and 
the expected full-length product was not obtained. To get the full-length product for 
replacement cloning required further extension using the PCR reaction with a long 
primers encoding the missing portions of the sequence (construct AA5.5). As a result, 
the second TEV protease cleavage site was introduced into the ICAD-L protein 
(construct AA5.6). 
5.3 TEV protease cleaves hICADL2TE\r  and activates hCAD in vitro. 
To test whether TEV protease can cleave hICADL2TE'  in vitro, cell-free extracts 
were made from the stable cell line (SC 5.2) expressing hICADL2TEV  :hCAD. hCAD 
expression in these cells was confirmed by RT-PCR (Fig. 5.3A). TEV protease was 
added to the extracts and the reaction was incubated at 37°C for two hours (Fig. 5.313 
and Q. As a result, the hICADL2Tll  protein was cleaved by TEV protease in vitro. 
ICAD N-terminal antibody was used to confirm that the cleavage of the first TEV 
protease site occurred (Fig. 5.313). The antibody recognises a 13 kDa band, which is the 
result of hICADL2TE'  protein cleavage with TEV protease. It was then confirmed that 
the second TEV protease site was cleaved in the hICADL2TF  protein. ICAD C-
terminal antibody was used for this purpose (Fig 5.3C). Again, a 10 kDa cleavage 
product of hICADL2TE'  protein was detected as a result of TEV protease cleavage of 
the hICADL2T'  second TEV protease site. In both cases, there was no full-length 
hICADL2Tl fragment left. 
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Fig. 5.3. hlCADL2TE\t  is cleaved in vitro. A stable cell line expressing hlCAD-L2TIV :hCAD in 
DT40 ICAD/CAD double knockout was analysed for hICAD-L 2TEV  cleavage. (A) A hCAD 
fragment was amplified in RT-PCR reaction. (B) Cell-free extract was prepared from the stable 
cell line. The cleavage of the first (B) and second (C) TEV sites in hlCADL2TEF  by TEV protease 
was confirmed, using ICAD N-terminal and C-terminal antibodies, respectively. The hlCAD-LT ' 
cleavage product is marked by an asterisk. 
One important question was whether the CAD protease released from the 
hICADL2TEV was catalytically active. Therefore, plasmid DNA was added to the 
reaction mixture of the hICAD-L2T ' cleavage with TEV protease (Fig 5.4). The 
reaction was performed separately in the presence and absence of caspase-3, as there 
could potentially be other proteins in the cell extract cleavable by caspase-3, which 
might normally inhibit CAD activation in non-apoptotic cytoplasm. Interestingly, after 
hICADL2TE' cleavage, CAD was activated and degraded the plasmid DNA (Fig. 5.4 
lanes 1-2, 5-6). This means that the hICAD-L2T ' protein can also efficiently work as a 
chaperone and produce active CAD capable of performing the DNA fragmentation 
reaction. Moreover, the presence or absence of caspase-3 did not make any difference 
for the reaction. 
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Fig. 5.4. hCAD is activated after hICAD-L 2TEV  cleavage by TEV protease in vitro. Extracts were 
prepared from stable cell lines expressing hlCAD-L2TEV :hCAD (lanes 1-8) in the ICAD"7CAU' 
double knockout (lanes 9-12) background. Plasmid DNA was added to each reaction mixture, 
either alone or with TEV protease, caspase-3, or both. Plasmid DNA was degraded in reactions 
where hCAD was released as a result of hICAD cleavage. The reaction was performed for one 
or two hours at 37°C. 
5.4 TEV protease is expressed, but does not cleave hICADL2TE\7 
protein in vivo. 
The Tet-On system was used to induce TEV protease in vivo (Fig. 5.5A). This 
system is composed of a reverse tetracycline-controlled transactivator (rtTA) and a 
promoter sequence containing tetracycline (tet) operators (Gossen et al., 1995). rtTA is a 
modification of tTA, which consists of Tet Repressor and the activating domain of 
virion protein 16 of herpes simplex virus (Gossen and Bujard, 1992). Tet repressor 
normally binds the tet operator in the absence of tetracycline. In the rtTA, a mutation in 
the Tet repressor reverses that property so that Tet repressor binds to tet operator only 
when tetracycline is present (Gossen et al., 1995). Therefore, the addition of tetracycline 
stimulates the binding of rtTA to the tet operator and induces the transcription of the 
desired gene. Doxycycline (Dox), a member of the tetracycline antibiotic group, was 
used to induce the Tet-On system in DT40 cells, as Dox is a more efficient inducer for 
the system than tetracycline (Gossen et al., 1995). 
Stable cell lines were constructed expressing TEV protease with two 5V40 NLS 
under the control of the Tet-On system, rtTA, hICADL2TE'  and hCAD. First, stable cell 
lines expressing hCAD and rtTA were selected (SC 5.1). hICADL2TI  was then 
introduced into these cell lines (SC 5.2). Finally, TEV protease was introduced under the 
control of the Tet-On system (SC 5.3). TEV protease expression was induced by adding 
doxycycline to two SC 5.3 cell lines. As TEV protease has a N-terminal Myc tag, its 
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Fig. 5.5. TEV protease is expressed, but does not cleave hICAD-L2T protein in vivo. Stable cell 
lines were constructed expressing hlCADL2TE/:hCAD in the DT40 ICAD/CAD double knockout. 
In addition, the TEV protease and rtTA for its regulation with the Tet-On system were expressed 
in two cell lines (a and b). (A) The diagram of the Tet-On system function. The expression of 
TEV protease was controlled by tet operator. rtTA binds to tet operator and activates the 
transcription only when Dox is added. TEV protease has nine copies of Myc tag on its N-
terminus and two 5V40 NLS on its C-terminus. (B) TEV protease was induced by addition of 
Dox in two independent cell lines (a and b). TEV protease expression was detected with Myc-tag 
antibody, which recognizes the Myc-tag located on the N-terminal part of TEV protease. (C) The 
level of expressed hlCADL2TE/  protein amount was monitored with ICAD antibody. 
Importantly, the DT40 cells did not die when TEV protease was induced in the model 
system. It was then checked whether hICADL2TE'  had been cleaved (Fig. 5.5C), but the 
hICAD-L2T1 ' band was unaltered after the induction of TEV protease. Therefore, in 
contrast to the in vitro experiment, TEV protease does not destroy the hICADL2T' 
protein in vivo. 
5.5 Mutant TEV protease is only partly active in DT40 cells 
As TEV protease was able to perform hICADL2TE'  cleavage in vitro but not in 
vivo, the problem could be in the activity of TEV protease in DT40 cells. Interestingly, 
one of the studies reported that a mutant version of TEV protease is significantly more 
efficient than the normal version (Kapust et al., 2001). This was achieved by a mutation 
that prevents the natural self-cleavage of TEV protease and its resultant progressive 
inactivation. The mutant version of TEV protease was also reported to be more 
efficiently catalytically active. As there appeared to be a problem with TEV protease 
activity in my study, I decided to examine whether the mutant TEV protease could 
cleave hICADL2TE'  in vivo. 
The mutant TEV protease (Kapust et al., 2001) was supplemented with two 
SV40 NLS on its C-terminus in a PCR reaction (construct 5.16). This was necessary to 
target TEV protease to the nucleus. The mutant TEV protease was in a fusion with MBP 
(Maltose-Binding Protein), which promotes TEV protease folding. MBP was previously 
shown to work as a chaperone in a fusion with other proteins (Kapust and Waugh, 
1999). Once TEV protease is synthesised, MBP is removed after TEV cleaves itself off 
the MBP-TEV construct using the internal TEV protease recognition site between two 
proteins (Fig. 5.6A). 
The stable cell line (SC 5.4) was assembled expressing mutant TEV protease 
under control of the inducible Tet-On system in the hICAD-L2T ':hCAD, rtTA cell line. 
The mutant TEV protease was induced by adding Dox and the cells were analysed for 
mutant TEV protease induction and hICADL2TE\  cleavage (Fig. 5.6). 
However, hICADL2TE'  was not cleaved after the induction of the mutant TEV 
protease with Dox in vivo. hICADL2TI  was also not cleaved by endogenous mutant 
TEV protease during the incubation of lysed cell-free extracts in vitro which could have 
potentially allowed mutant TEV protease to cleave hICAD-L2T '. Under these 
conditions TEV would be expected to cleave hICADL2Tl  even if they were 
mislocalised in different subcellular compartments in vivo. However, hICAD12Th'l  was 
cleaved when an exogenous TEV protease was added to the reaction mixture, indicating 
that its two TEV sites are accessible to the protease. 
Interestingly, the TEV protease was able to self-cleave off the MBP in vivo (Fig. 
5.6C lane 3). This was achieved through the cleavage of the TEV protease site between 
MBP and mutant TEV protease in vivo. However, the activity of TEV protease was still 
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Fig. 5.6. Mutant TEV protease is partly active in DT40 cells but insufficiently to cleave hICAD-
L2TEV. (A) Diagram of the MBP - mutant TEV protease construct. The construct consists of MBP 
(Maltose-Binding Protein), followed by the TEV recognition site and mutant (m) TEV protease. 
Once synthesized, mTEV protease uses the TEV site to cleave itself from the MBP. The 
released mTEV protease has His tag on its N-terminal and two SV40 NLS on its C-terminal. (B) 
Extracts were prepared from stable cell lines expressing MBP-mTEV protease together with rtTA 
for its regulation (lanes 1-6) and hlCADL2TE\I:hCAD  (lanes 1-8) in the !CAD'7CAD" double 
knockout background. The expression of MBP-mTEV was induced by the addition of Dox for 24 
hours before cell extract preparation (lanes 1-3). In addition, TEV protease was added to the 
cell-free extracts in vitro (lanes 1 and 4) and the reactions were performed at 37°C for two hours 
(lanes 1-2 and 4-5). (C) The cleavage of the MBP-mTEV construct was detected with MBP 
antibody (lanes 1-3). MBP cleavage product is marked by an asterisk. The estimated size of full-
length uncleaved MBP-mTEV product is 75 kDa. 
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5.6 Introduction of PreScission protease cleavage sites into hICAD-L 
The expression of TEV protease in vivo did not result in successful cleavage of 
the hICADL2TE'  protein. Therefore, it was decided to change the strategy and to design 
an alternative way to achieve hICAD-L cleavage. 
PreScission protease is one of the most site-specific proteases (Cordingley et al., 
1990; Walker et al., 1994). It is a fusion protein derived from GST (glutathione S-
transferase) and human rhinovirus 3C protease (Leong et al., 1992), and was designed 
for the in vitro cleavage of GST affinity tags from the purified proteins. In addition, the 
GST tag in PreScission protease allows the removal of the enzyme from the reaction 
mixture after cleavage. PreScission protease is used for protein cleavage in vitro. 
However, there is as yet no report of artificially engineered model systems for in vivo 
cleavage with PreScission protease. 3C protease, from which PreScission protease is 
derived, is able to perform the cleavage of the viral polyprotein precursor during viral 
infection of human cells. Therefore, an artificial model system for site-specific in vivo 
protein cleavage with PreScission protease could have a potential application in human 
and vertebrate cells, including DT40. I decided to determine whether PreScission 
protease can be used for in vivo cleavage of target proteins by testing it on a model 
system involving human ICAD-L with two PreScission sites (hICAD-L2 ) and hCAD. 
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hICAD-L First site 	 hICAD-L Second site 
-Vat- 	 -Ser- 	 -Vat- 	 -Thr- 
	
PreScission 	 Presclsslon 
-Val-Leu-GIu-Val-Leu-Phe-Gln- J.Gly-Pro-Ser- 	-VaI-Leu-Glu-VaI-Leu-Phe-Gln+Gly-Pro-Thr- 
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Fig. 5.7. Strategy for replacement of two caspase-3 sites in hICAD-L protein with two 
PreScission protease sites Two caspase-3 sites in hICAD-L protein were replaced by two eight 
amino acid PreScission protease recognition sites. The fragment of hICAD-L protein containing 
two PreScission protease sites was amplified in a two-step PCR reaction. In the first step, a 
fragment was amplified using oligos encoding PreScission protease recognition sites. In the 
second step, in the same PCR reaction, the fragment was further extended to allow replacement 
cloning using EcoRV and BIpl sites. The desired fragment was then introduced into the hICAD-L 
cDNA. 
To do this, two caspase-3 recognition sites in the hICAD-L protein were replaced with 
two PreScission protease recognition sites (Fig. 5.7). The hICAD-L2 ' protein was 
engineered using a strategy based on that used to create the hICAD-L 2TEV  protein. Long 
primers containing sequences encoding PreScission protease recognition sites were used 
in a PCR reaction to amplify the DNA fragment of ICAD-L protein between cleavage 
sites together with some flanking sequences. Next, the PCR reaction was continued to 
extend the 3' part of hICAD-L protein to reach the B/pT site (construct 5.24). This 
allowed replacement cloning of the amplified fragment into hICAD-L protein using 
EcoRV and BlpI sites. As a result, the hICAD_CPRE  protein was constructed (construct 
5.25). 
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5.7 New technology for targeted protein cleavage in vivo with 
PreScission protease. 
To test whether PreScission protease can cleave hICAD-L21RE   protein in vivo, it 
was decided to establish stable cell lines expressing both the hICAD-L21RE   protein and 
PreScission protease at the same time under constitutive expression. These stable cell 
lines were constructed starting with the ICAD/CAD double knockout, so there was no 
CAD present to be activated. Five stable cell lines were isolated after transfection of the 
constructs encoding hICAD-L2'RE  and PreScission protease; all five showed detectable 
PreScission protease expression, which was confirmed by RT-PCR (Fig. 5.8A). hICAD-
L2PRE mRNA was expressed in three (SC 5.5) out of five of these stable cell lines, and 
these cell lines were chosen for further analysis. Surprisingly, although these cell lines 
expressed both PreScission protease and hICAD-L2PRE  mRNA, there was no detectable 
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Fig. 5.8. Analysis of stable cell lines expressing PreScission protease and hlCAD-L2PRE  
(A) PreScission protease and hlCAD-L2PRE  expression was confirmed by RT-PCR. Top panel: 
Five clones (a, b, c, d, e) were tested for PreScission protease expression (lanes 1-5). Also, 
ICAD/CAD double knockout (lane 6) and plasmid DNA encoding the PreScission protease gene 
(lane 7) were used for the reaction. The RT-PCR negative control (lanes 8-13) did not have 
reverse transcriptase added to synthesize cDNA from RNA. Bottom panel: The same clones 
were tested for hlCAD-L2PRE  expression. The stable cell line expressing hlCADL2T  (lane 7 and 
14) was used as a control for hICAD-L amplification. (B) Analysis of hICAD-L expression by 
immunoblotting in stable cell lines (a, b, e) expressing PreScission protease and hlCAD-L2 PRE 
(lanes 1-3), ICAD/CAD double knockout (lane 4) and a cell line expressing hlCAD-L2T ':hCAD 
(lane 5). ICAD protein was detected with ICAD N-terminal antibody. 
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To further investigate the stable cell line (SC 5.5b) expressing PreScission 
protease, it was transiently transfected with the hICAD-L21 	construct to express 
increased level of hICAD-L2PRE  protein (Fig 5.9A). Transient transfection was 
performed by nucleofection, which is characterized by a high transfection efficiency and 
consequently often achieves a high expression level (Martinet et al., 2003). The cell line 
had the hICAD-L 2PRE  protein expressed after the transient transfection. Interestingly 
there were two fragments 12 kDa and 26 kDa corresponding to the predicted size of the 
cleaved fragments of hICAD-L 2PRE  protein (Fig. 5.9). Notably, the size of one fragment 
was 12 kDa, which corresponds to the N-terminal fragment of ICAD-L protein formed 
after the cleavage of the first site. Another hICAD-L 2PRE  fragment detected with ICAD 
N-terminal antibody, had a size 26 kDa. According to the diagram (Fig. 5.9C), this 
might correspond to the N-terminal fragment of hICAD-L 2PRE  protein where the second, 
but not the first, site is cleaved. Finally, in this experiment, proteasome inhibitor MG 132 
was used to prevent the protein degradation. The cell extracts from the analysed cell 
lines were also incubated in vitro to stimulate the possible additional cleavage of 
hICAD-L 2PRE  by PreScission protease. 
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Fig. 5.9. PreScission protease cleaves hlCAD-L2PRE  in vivo. 
(A) Transient transfection of hlCAD-L2PRE into stable cell line expressing PreScission protease 
(lanes 1-3) or ICAD/CAD double knockout (lanes 4-6). The cell lines were also treated with 
proteosome inhibitor MG 132 for 6 hours before sample collection (lanes 2 and 5) or cell extracts 
were incubated in vitro for 2 hours at 37° C in the presence of MG 132 (lanes 3 and 6). hICAD-
L2PRE was detected with ICAD N-terminal antibody. hlCAD-L2PRE  cleavage product is marked by 
an asterisk. (B) Shows a longer exposure of this blot. (C) Diagram of ICAD-L protein showing 
the predicted size of PreScission cleavage products that could potentially be recognised by 
ICAD N-terminal antibody. 
5.8 Transient transfection of PreScission protease into hICAD-
L2 'MAD stable cell lines. 
To determine whether CAD can kill the cell once it is activated after cleavage of 
the hICAD-L'PRE protein with PreScission protease, two stable cell lines (SC 5.7) were 
constructed expressing the hICAD-L2PRE  protein and hCAD. The PreScission protease-
expressing vector was transfected into these cell lines by nucleofection. As a control, the 
cell lines were transfected with the vector alone. At one and two days after 
nucleofection, the number of living cells was measured by the trypan blue exclusion 
method. The percent difference in viability between cells transfected with PreScission 
protease and the vector alone (PreScission protease transfection/vector alone 
transfectionx 100) is shown in Fig. 5.10. The percentage of living cells transfected with 
PreScission protease was always lower when compared to those transfected with vector 
alone. At 0 hour, equal amounts of cells were added to the transfection with PreScission 
protease or the vector alone. Transfection of cultures with PreScission protease resulted 
in cell death, including the ICAD/CAD double knockout where no targets of PreScission 
protease are predicted to be present. However, the degree of cell death was consistently 
higher in hICAD-L21 :CAD cell lines than for the ICAD/CAD double knockout cell 
line. This was statistically significant at 24 hours after transfection. 
PreScission transfection/ 
mock transfection=Iiving cells 
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Fig. 5.10. Stable cell lines expressing WCAD-L 2PRE:hCAD are more susceptible to cell death 
after transient transfection with PreScission protease than ICAD/CAD 	cells. Plasmid 
expressing PreScission protease or vector alone (mock transfection) were transfected into stable 
cell lines (a and b) expressing hlCAD-L2PRE  :hCAD in the [CAD/CAD double knockout 
background. The number of living cells was calculated in both transfections at 24 and 48 hours 
using the trypan blue exclusion method. The number at 0 hour is estimated. The difference in 
the number of living cells observed after transfection with PreScission protease and mock 
transfection is indicated as a percentage of the total in the graph. 
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5.9 Discussion 
To test whether CAD activation can kill the cell, several model systems were 
constructed using ICAD that could be cleaved with TEV and PreScission proteases. The 
PreScission protease was used here for the first time in order to test its applicability as a 
tool for site-specific protein cleavage in vivo. 
To demonstrate CAD's ability to cause cell death in the absence of initial 
apoptosis, I decided to cleave its inhibitor ICAD, modified to incorporate two TEV sites. 
It is known that TEV protease needs to have efficient access to its cleavage site target to 
perform the reaction (Ehrmann et al., 1997). Therefore, it was necessary to confirm 
whether TEV protease could access its cleavage sites in the hICADL2TE'  protein. In 
fact, both TEV recognition sites in hICADL2TE\'  were cleaved by TEV protease in vitro. 
This resulted in CAD activation in vitro, as detected by the degradation of plasmid 
DNA. Therefore, the artificially designed hICADL2TE'  protein was functional and able 
to work as both a chaperone and inhibitor for CAD. 
Achieving CAD activation in vivo, however, proved to be a much more difficult 
task. TEV protease was induced in vivo and efficiently expressed, but the expressed 
protease either lacked the ability to cleave the hICADL2T'  protein, or did not cleave it 
at significant levels. The later would be particularly important if hICAD-1 2T '/hCAD 
ratio was high. Then, more TEV activity would be necessary to cleave the inhibitor pool 
before CAD could be activated. In addition, I can not exclude the possibility that some 
low level cleavage of hICAD-L2T ' protein by TEV protease may occur and thus results 
in the variability of protein amount in Fig. 5.5. Alternatively, the variability may be due 
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to the differences in sample loading. In any case, the complete hICAD_j'2TEV  protein 
cleavage and the cell death that could be the result of it, did not occur in vivo thus 
requiring the development of alternative approaches to destroy the protein. The lack of 
protein cleavage was not due to inaccessibility of the sites due to the three-dimensional 
structure of the hICAD-L2T1 " protein, as TEV protease could cleave hICADL2TE\l in 
vitro. In cells, however, TEV protease and hICAD-L2T ' could potentially be located in 
different sub-cellular compartments. To avoid this situation, TEV and mutant TEV 
protease were targeted to the nucleus with two SV40 NLS. It must also be noted that the 
version of TEV protease with two SV40 NLS sequences was the same as that used in 
yeast studies (Uhlmann et al., 2000) in which the TEV protease with added NLS was 
localised in the nucleus. As hICADL2TE\'  has its own NLS, both proteins would be 
predicted to target to the nucleus using their localisation signals. 
Another possible reason why TEV protease did not work in vivo is that it might 
lack sufficient activity to cleave hICAD-L2T ' in vivo. Although TEV protease has been 
used in yeast cells and E. coli for site-specific protein cleavage in vivo (Ehrmann et al., 
1997; Mondigler and Ehrmann, 1996; Smith and Kohorn, 1991; Uhlmann et al., 2000; 
Yang et al., 2005), I am unaware of reports of its successful application in vertebrate 
cells. This is somewhat surprising, considering that there are numerous experiments for 
which it might be reasonable to extend the use of TEV protease cleavage technology 
from yeast to vertebrate model systems. 
I decided to try to solve the potential problem posed by the lack of TEV protease 
activity by using a mutant TEV protease, which was reported to be more stable and 
catalytically active than the normal version (Kapust et al., 2001). However, cleavage of 
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the hICADL2TE'  protein still did not occur in vivo when this mutant TEV protease was 
expressed. As in the previous case with normal TEV protease, hICADL2TE\'  protein was 
cleaved only in vitro when exogenous TEV protease was added. Importantly, mutant 
TEV protease expressed in vivo was not able to cleave the hICAD-L2T ' protein even in 
lysed cell-free extracts, where cellular compartmentalisation barriers that could 
potentially prevent access to hICAD-L2T ' protein would be absent. Interestingly, TEV 
protease was able to self-cleave off the MBP in vivo, so it must have had some activity 
in DT40 cells. That activity, however, was not enough to cleave the hICAD-L2T ' 
protein in vivo. One possibility is that TEV protease expressed in vivo is somehow 
inactivated - e.g. by phosphorylation or binding of an inhibitor. 
At present, I am unaware of any model system available for site-specific protein 
cleavage in vertebrate cells. As a result, there is no system to be used to test whether 
CAD activation outside of apoptosis can trigger cell death. As TEV protease originates 
in a plant virus (Carrington and Dougherty, 1987), its performance has been 
evolutionally optimised to work in plant cells. This is possibly one of the reasons why 
TEV protease does not work efficiently in DT40 cells. By contrast, PreScission protease 
originates in human rhinovirus (Cordingley et al., 1989; Hanecak et al., 1982) and thus 
has been evolutionally adapted to work in human cells. Therefore, it has the potential to 
be used for site-specific protein cleavage in vertebrate cells. 
In the present study, I obtained evidence suggesting for the first time that 
PreScission protease can cleave a target protein in vivo. PreScission protease appeared to 
cleave the hICAD-L2PRE protein in vivo in a stable cell line expressing the enzyme. 
Moreover, the isolation of a stable cell line expressing PreScission protease indicates 
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that DT40 cells can tolerate the enzyme, at least when it is not overexpressed. After 
transient transfection of the hICAD-12PRE  protein into a stable cell line expressing 
PreScission protease, fragments corresponding to the size of the predicted cleaved 
products of the hICADL2PRE  protein were detected. That the levels of the cleaved 
product were significantly less than that of a full-length hICAD-1 2PIE  protein could 
potentially be explained if the cleavage could be inefficient for an as yet unknown 
reason. Alternatively, it is possible that the cleaved product of hICADL2Tl\I  might be 
rapidly degraded in vitro. In stable cell lines expressing hICAD-L:hCAD, it was not 
possible to detect the cleaved product of the hICAD-L protein after its caspase-3 
cleavage in vivo. It is possible that hICAD-L2PRE  protein expression in the nucleofection 
experiment was so robust that relatively large amounts of its cleaved fragment were 
produced, permitting its detection. 
Once PreScission had been demonstrate to apparently cleave hICAD-L2'RE  in 
vivo, I attempted to construct an inducible Tet-On system with PreScission protease 
based on the hICADL2  E:hCAD stable cell line. However, I was unable to isolate cell 
clones expressing PreScission protease using the system that had worked previously to 
induce TEV protease (data not shown). This could possibly be due to a basal level of 
expression in the Tet-On system without induction (Sipo et al., 2006). Such expression 
could produce enough PreScission protease for hICAD-12PRE  cleavage and hCAD 
activation. If that resulted in cell death, such clones would die in the selection process. 
As an alternative, transiently transfected PreScission protease could be used to 
induce hICAD-L21RE   cleavage in these cells. In fact, transiently transfection of 
PreScission protease does result in a decrease in the viability of DT40 cell lines, 
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particularly those expressing hICAD-L21 :hCAD. Nucleofection can result in the high 
level of expression of the transfected protein (Martinet et al., 2003). Such high levels of 
PreScission protease might be toxic to DT40 cells. Although, PreScission protease is a 
site-specific protease, but it might cleave sequences resembling its recognition site with 
reduced efficiency. Such side effects could potentially be important when there is an 
overexpression of the PreScission protease. Interestingly, after PreScission protease 
transfection, the number of living cells expressing hICADL2 E:hCAD was less than 
that seen following transfection of double knockout cells. These data were statistically 
significant at 24 hours in two independent cell lines. Therefore, although I recognise that 
considerable amount of work remain to be done, I hypothesize based on these 
preliminary observations that CAD nuclease can contribute to cell death after its 
inhibitor hICAD-L2PRE  protein is cleaved by PreScission protease. 
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6. The role of ICAD-S in vivo 
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6.1 Introduction. 
There are two forms of ICAD protein in cells, ICAD-LIDFF-45 and ICAD-
SIDFF35 (Enari et al., 1998; Gu et al., 1999; Sakahira et al., 1998), that result from 
alternative splicing of a single pre-mRNA (Kawane et al., 1999). Most studies have 
focused on ICAD-L, and the function of ICAD-S remains obscure. ICAD-S does not 
appear to function as a chaperone for CAD folding, since it does not support the 
production of active CAD if it is expressed in ICAD mouse MEFs (Nagase et al., 
2003). Nevertheless, ICAD-S was able to work as an inhibitor for CAD in vitro (Gu et 
al., 1999; Sakahira et al., 1999). ICAD-S in rat neurons prevents CAD activation (Chen 
et al., 2000). No ICAD-L protein, however, was detected in this system, making it 
unclear just how CAD had been chaperoned, how ICAD-S had become associated with 
CAD, and what its specific function in the cell was. Furthermore, tissue-specific 
differences in the quantity of ICAD-L and ICAD-S have been observed (Chen et al., 
2000; Kawane et al., 1999), and recent studies show that the ratio of ICAD-L and ICAD-
S can be regulated in a single cell type (Li et al., 2005). 
In the experiments described here, I used the chicken ICAD knockout and the 
ICAD/CAD double knockouts to identify the function of ICAD-S in vivo. 
6.2 Analysing chicken ICAD ORF for alternative splice forms and 
constructing chicken ICAD-L and ICAD-S. 
The chicken ICAD genomic region was isolated by Dr Kumiko Samejima and 
sequenced by Matthew A. Sims at GlaxoSmithKline. Dr Samejima performed the 
identification of the chicken ICAD ORF and the analysis of the ICAD exon/intron 
boundaries for the genomic sequence. The chicken ICAD protein has six exons and five 
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introns (Fig. 6. 1). A cICAD-L mRNA is formed from the six ICAD exons. Studies done 
in human, rat and mouse model systems also identify a shorter version of the ICAD 
protein ICAD-S (Chen et al., 2000; Enari et al., 1998; Gu et al., 1999; Sakahira et al., 
1998). The formation of the ICAD-S transcript in mice happens by alternative splicing 
when intron 5 is left unspliced from the initial transcript (Kawane et al., 1999). A stop 
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Fig. 6.1. Diagram of the chicken ICAD ORF and ICAD alternative splice forms synthesized from 
it. Chicken ICAD ORF consists of six exons and five introns. cICAD-L is synthesized from six 
exons. The cICAD-S alternative splice form is synthesized from the first five exons and the part 
of the fifth intron before the intrinstic stop codon. cICAD-L and cICAD-S proteins have two 
caspase-3 cleavage sites. The percentage of the amino acid sequence identity between chicken 
and human splice forms is indicated. 
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The possibility of alternative splicing of the ICAD transcript in chickens was 
analysed using chicken ICAD ORF, and the stop codon was identified in chicken ICAD 
intron 5. Therefore, alternative splicing of cICAD-S can happen in DT40 cells in a way 
similar to that of mouse cells. While this work was in progress, data confirming the 
occurrence of the two ICAD splice forms ICAD-S and ICAD-L in DT40 cells was 
published (Li et al., 2005). Therefore, it was decided to engineer chicken ICAD-L and 
ICAD-S proteins and proceed directly to the analysis of their function. 
Chicken ICAD-L (construct AA6-2) was engineered from an incomplete cICAD-
L cDNA isolated by Dr. Samejima using long primers to introduce the missing 
sequences. cICAD-S (construct AA6-8) was engineered in a PCR reaction from the 
cICAD-L cDNA. The 3' end of cICAD-S, which is different to that of cICAD-L, was 
introduced via a long primer sequence based on the cICAD genomic region sequencing 
data. 
6.3 Chicken ICAD-S function in DT40 cells. 
Once chicken ICAD-L and ICAD-S were isolated, I decided to identify their 
function in DT40 cells. It was particularly interesting to characterise the function of the 
ICAD-S splice form, as almost no data is available for its function in vivo. To identify 
the function of ICAD-S, I took advantage of the ICAD and ICAD/CAD double 
knockouts, as they allowed any splice form to be expressed in the absence of the 
endogenous ICAD protein. 
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Stable cell lines expressing chicken ICAD-S were isolated in the ICAD knockout 
(SC6.4). These stable cell lines were analysed for the presence of DNA fragmentation 
after the induction of apoptosis with 10 jiM etoposide (Fig. 6.2). There was no DNA 
fragmentation in any of these cell lines. Thus, their phenotype resembled that of the 
ICAD knockout. By contrast, the DNA fragmentation progressed normally in DT40 wt 
cells exposed to the drug. The expression of chicken ICAD-S mRNA was analysed in 
the isolated stable cell lines (Fig 6.2). It was expressed in three cell lines (Fig. 6.213 lanes 
1-3) and absent from one (Fig. 6.2B lane 4). None of these cell lines, however, was able 
to develop detectable DNA fragmentation. As a positive control, the total RNA of the 
DT40 wt was used. Amplification was also carried from plasmid DNA with the cICAD-
S gene. In both cases, there was a band corresponding to the fragment of cICAD-S that 
was amplified using these specific primers. The amplified ICAD-S band in DT40 wt was 
significantly weaker than in the stable cell lines. There was another band observed in 
amplifications of DT40 wt RNA with a higher yield. This was absent in the negative 
control where no reverse transcriptase was added, and may potentially represent another 
splice form of the ICAD protein. I then attempted to amplify a longer fragment of 
chicken cDNA, but the amplification of long cDNA fragments with different ICAD 
cDNA primers was not successful. In general, it was only possible to efficiently isolate 
small fragments of chicken ICAD cDNA by RT-PCR. 
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Fig. 6.2. DNA fragmentation is absent in stable cell lines expressing cICAD-S in the chicken 
ICAD knockout. (A) DNA fragmentation. Genomic DNA samples were collected at 0 and 4 hours 
after the induction of apoptosis with 10 pM etoposide. Four stable cell lines selected for the 
presence of cICAD-S plasmids were tested (a, b, c and d). ICAD knockout was used as a 
negative control and DT40 wt as a positive control. (B) RT-PCR reaction to detect the 
expression of cICAD-S in the analysed cell lines. The primers used for RT-PCR reactions were 
designed to amplify only a part of the cICAD-S cDNA. The RT-PCR negative control was a 
reaction in which no reverse transcriptase was added during the first-strand synthesis. 
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As there was no DNA fragmentation in cells expressing only cICAD-S, it was 
necessary to confirm that the long version of chicken ICAD protein - cICAD-L together 
with chicken CAD - can perform the function of reconstructing DNA fragmentation in 
the ICAD/CAD double knockout. I originally planned to construct a stable cell line 
containing chicken ICAD-L tagged with a C-terminal triple tandem purification tag (S-
tag-TEVsite-SBP-tag-His - SATH-tag) for the purification of the interacting proteins 
(Fig. 6.3A). S-tag is a fragment of RNAse A that binds with high affinity during protein 
purification to another component of RNAse A, S-protein (Karpeisky et al., 1994). The 
SBP (Streptavidin Binding Peptide) tag has a high affinity for streptavidin (Keefe et al., 
2001), another useful property for protein purification. The TEV site between S-tag and 
SBP could be used to cleave the tagged protein off the streptavidin beads. Finally, the 
His-tag can provide an additional step for tandem protein purification (Terpe, 2003). 
The ICAD/CAD double knockout was transfected with cICAD-L-SATH-tag and 
cCAD plasmids and stable cell lines were selected (e.g. SC6.5), then tested for DNA 
fragmentation upon induction of apoptosis with 10 jiM etoposide (Fig. 6.3B). DNA 
fragmentation was observed in the cICAD-L-SATH:cCAD stable cell line (Fig. 6.3B), 
but not the double knockout cells. Therefore, cICAD-L protein tagged with C-terminal 
SATE tag is functional in DT40 cells. 
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Fig. 6.3. DNA fragmentation is 
present in a cICAD-L-
SATH:cCAD stable cell line 
constructed starting with the 
ICAD/CAD double knockout. 
(A) Diagram of the cICAD-L-
SATH tag construct. The C-
terminal SATH tag consists of 
an S-tag, TEV protease site, 
SBP (Straptavidin Binding 
Peptide) and His-tag. (B) 
Genomic DNA samples from 
cICAD-L-SATH:cCAD and the 
control stable cell line were 
collected four hours after the 
induction of apoptosis with 
etoposide. 
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6.4 Human ICAD-S also does not work as a folding chaperone for CAD 
in vivo. 
Since human ICAD-L plus CAD could reconstitute the DNA destruction system 
in DT40 ICAD'7CAIY' double knockout cells and there are antibodies available for the 
detection of human proteins, I decided to ask whether a similar rescue could be obtained 
using hICAD-S in place of hICAD-L. After the induction of apoptosis by etoposide, 
hICAD-S was cleaved in these (SC6.3) cells (Fig. 6.4A lanes 1-3), but no DNA 
fragmentation could be detected in these cell lines (Fig. 6.4A lanes 1-3). Furthermore, 
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chromatin condensation did not proceed beyond stage I, with small balls of chromatin 
distributed around the nuclear periphery (Fig. 6.413). Therefore, hICAD-S cannot 
replace hICAD-L as a chaperone in vivo for the folding of active CAD. 
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Fig. 6.4. 	hICAD-L but not hICAD-S 
supports the production of active hCAD in 
vivo. (A) Apoptosis was induced by 10 pM 
etoposide in stable cell lines expressing 
hICAD-S:hCAD (lanes 1-3) and hICAD-
L:hCAD (lanes 4-6) in the chicken 
ICAD:CAD 	background. (upper) 
Genomic DNA was isolated at 0, 2 and 4 
hours after induction of apoptosis. (lower) 
The cleavage of hICAD-S and hICAD-L 
was detected with hICAD N-terminal 
antibody. (B) Images of cells before and 
after induction of apoptosis (0 and 4 
hours). Stage II chromatin condensation 
was absent in cells expressing hICAD-
S:hCAD and present in cells expressing 
hICAD-L:hCAD. 	Data represent a 
minimum of at least three independent 
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6.5 ICAD-S inhibits CAD in vivo. 
Importantly, ICAD is essential not only for the folding of active CAD, but also 
for its subsequent inactivation until an appropriate apoptotic stimulus is detected. I 
therefore used the humanized cell system to test whether ICAD-S can fill this second 
role as an inhibitor of CAD in vivo. To do this, I constructed a form of hICAD-S that 
was resistant to cleavage by caspases, but could be cleaved at the same sites by the viral 
TEV protease. I then introduced ICAD-S2T ' into the humanized DT40 cells in which 
endogenous chicken ICAD and CAD had been replaced with hICAD-L and hCAD (Fig. 
6.5A lanes 1-9). In these cell lines (SC6. 1), hICAD-L acts as a folding chaperone and 
inhibitor for hCAD. Treatment of these cell lines with etoposide resulted in activation of 
the intrinsic pathway of apoptosis, leading to caspase activation and cleavage of hICAD-
L but not hICADS2TEV  (Fig. 6.5A lanes 1-9). Thus, if hICAD-S2T ' can bind and inhibit 
hCAD in vivo these cells should fail to show any activation of CAD nuclease. 
Indeed, after induction of apoptosis in the humanized cells expressing hICAD-
S2TEv hCAD activation was prevented (Fig. 6.5A lanes 1-9). In clones expressing high 
levels of hICADS2TEv  no evidence DNA fragmentation or apoptotic body formation 
was observed (Fig. 6.5A lanes 1-3, Fig 6.513). More variable results were obtained in 
cell clones expressing lower levels of hICADS2T.  In one stable cell line expressing 
lower levels of hICADS2TEV,  no DNA fragmentation was observed (Fig. 6.5A lanes 4-
6). In a second hICAD-S2T '-expressing clone, low levels of DNA fragmentation could 
be observed (Fig. 6.5A lanes 7-9) and apoptotic bodies were formed, albeit —three-fold 
less efficiently than in the "wild type" humanized cells expressing only hICAD-L plus 
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Fig. 6.5. ICAD-S can inhibit CAD in viva Stable cell lines expressing different levels of hICAD-
S2TEV were constructed starting with the humanized cell line expressing hICAD-L:hCAD in the 
ICAD"7CAD' double knockout. (A) Genomic DNA was isolated at 0, 2 and 4 hours after 
induction of apoptosis (top). The status of hICAD-L and hlCADS2TEv  was monitored by 
immunoblotting. hICAD-L but not hlCADS2TE/  was cleaved by caspase in vivo during the 
induction of apoptosis. One of the cell lines had a high level of hlCAD-S2T ' (lanes 1-3) Two 
other cell lines had a lower level of hlCADS2TE/  (lanes 4-9). A cell line expressing high level of 
caspase-cleavable hICAD-S was used as a control (lanes 10-12). (B) Images of cells before 
and after induction of apoptosis (0 and 4 hours). DNA was stained with DAPI. Histograms show 
the percentage of cells with normal, stage I and stage II chromatin condensation. The 
experiment was done at least three times with over 300 cells counted for each independent 
experiment. 
114 
hCAD (Fig. 6.513). There was no obvious difference in the levels of hICAD-S2T ' 
protein in these two cell lines so the explanation for the difference is not clear. 
Importantly, in all cell lines expressing higher levels of hICAD-S2T ', hCAD activation 
was completely abolished. 
6.6 TEV protease cleaves ICADS2TE\T  in vitro and releases active CAD 
An in vitro experiment confirmed that both hICAD-L and hICAD-S can 
efficiently perform the function of inhibiting hCAD and that cleavage of both inhibitors 
is required for hCAD activation. In this experiment, I prepared extracts from humanized 
DT40 cells (SC6. I) in which endogenous ICAD and CAD had been replaced by hICAD-
S2TEV plus hICAD-L plus hCAD (Fig. 6.6 lanes 1-4). In those extracts, added caspase-3 
selectively cleaves ICAD-L but not ICAD-S2T ', whilst added TEV selectively cleaves 
ICAD-S2T ' but not ICAD-L. Using this system, I observed CAD activation only when 
both caspase-3 and TEV were added to the extracts (Fig. 6.6 lane 4). 
In a control experiment, I prepared extract from a stable cell line (SC4.10) 
expressing hICAD-L plus hCAD. In that extract, plasmid DNA was degraded when 
caspase-3 was added to the reaction mixture, but not when TEV protease was added 
(Fig. 6.6 lanes 5-8). This confirms the well known activation of hCAD following 
hICAD-L cleavage by caspase-3. 
To test whether the replacement of caspase-3 sites with TEV protease sites 
affected the ability of ICAD-L to act as a folding chaperone function for production of 
active CAD I constructed stable cell lines (SC5.2) expressing hICAD-L2T1 ' plus hCAD 
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lines were analysed in vitro, the addition of TEV protease was found to release active 
CAD, leading to the cleavage of plasmid DNA (Fig. 6.6 lanes 11-12). Therefore, 
replacing the two caspase cleavage sites of hICAD-L protein with TEV sites did not 
affect its chaperone and inhibitor function. Furthermore, this experiment reveals for the 
first time that under non-apoptotic conditions, specific cleavage of ICAD, is the only 
requirement for CAD activation in cell-free extracts. 
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Fig. 6.6. hCAD is activated in vitro after the cleavage of hICAD in non-apoptotic extracts. 
Extracts were prepared from stable cell lines expressing hlCADS2TE/:hlCAD.L:hCAD (lanes 1-
4), hICAD-L:hCAD (lanes 5-8) and hlCADL2TE:CAD (lanes 9-12) in the !CAD-I-/CAD  double 
knockout (lanes 13-16) background. Plasmid DNA was added to each reaction mixture either 
alone, or together with caspase-3, TEV protease or both. Plasmid DNA was degraded in 
reactions where hCAD was released as a result of hICAD cleavage. 
As a final control, when either caspase-3 or TEV protease was added to cell-free 
extracts prepared from ICAD 17CAD' double knockout cells, no plasmid DNA 
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degradation was observed. Therefore, neither protease is activating another latent 
nuclease, such as endonuclease G, in the cell-free extracts. 
17 
6.8 Discussion. 
ICAD splice forms ICAD-L and ICAD-S are ubiquitously present in human, 
mouse, rat and chicken cells (Chen et al., 2000; Kawane et al., 1999; Li et al., 2005). 
Interestingly, while the ICAD-L splice form has been extensively studied, the function 
of ICAD-S remains elusive. 
I constructed a humanized system by expressing hICAD-L and hCAD cDNAs in 
chicken DT40 cells lacking the entire ORFs for ICAD and CAD. In those cells, normal 
DNA degradation and chromatin condensation were observed following addition of 
etoposide. In this system, hICAD-S was unable to replace hICAD-L, thereby confirming 
an earlier observation that ICAD-S is unable to function as a chaperone to promote the 
folding of active CAD (Nagase et al., 2003). 
To test the role of ICAD-S as an inhibitor of CAD in vivo and in vitro, I created 
an allele of ICAD-S in which the two caspase cleavage sites had been replaced by TEV 
protease cleavage sites (ICAD-S2T ). When ICAD-S was expressed at high levels in 
the humanized DT40 cells (ICAD/CAD double knockout expressing hICAD-L and 
hCAD) it was able to completely abolish both DNA cleavage and stage II chromatin 
condensation following the addition of etoposide. Thus, ICADS2TE'  can bind to CAD, 
which has been liberated following the cleavage of ICAD-L and inhibit its nuclease 
activity. 
The results of this experiment were confirmed using an in vitro assay in which 
cell-free extracts expressing various combinations of hICAD-L, hICAD-L2T1 ", hICAD-
S, hICAD-S2T ' and hCAD were treated either with active caspase-3, with TEV 
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protease, or both and examined for the activation of CAD nuclease. These experiments 
showed clearly that either ICAD-L or ICAD-S can fully inhibit CAD activity, and that 
providing CAD has been translated in the presence of ICAD-L, cleavage of ICAD by 
either protease can release active CAD. 
I originally designed this system to examine whether cleavage of ICAD in a non-
apoptotic context in vivo would result in CAD activation and cell death. This approach 
used as a model experiments in which expression of TEV in budding yeast was used to 
cleave cohesin component Sccl/Mcdl and release cells into anaphase (Uhlmann et al., 
2000). However, after almost two years of attempts using multiple vector systems for 
the expression of nuclear and cytoplasmic TEV protease in DT40 cells, I was able to 
express TEV but could never demonstrate any cleavage of ICADL2TEv.  I do not know 
the reason for this lack of TEV cleavage in living DT40 cells, but it is unlikely to result 
from inaccessibility of the TEV sites, as both ICADL2TE'  and ICAD-S2TEV  were 
efficiently cleaved in cell-free extracts by exogenous TEV. 
This system could also be used to ask whether DT40 cells contain other activities 
that can inhibit CAD, should ICAD-L be removed. It has been proposed that 
nucleophosmin/1323 (Ahn et al., 2005) and CIIA (Cho et al., 2003) can fulfil this role. 
These inhibitors have been proposed to modulate CAD function either in normal cells or 
during apoptosis. Inhibiting CAD could be one of several functions of B23 that would 
be expected to be lost once B23 is cleaved by caspase-3 in apoptosis (Chou and Yung, 
2001). In contrast, the cleavage of CIIA has not been reported in apoptosis. 
To address the importance of these or any other possible alternative inhibitors of 
CAD function, I expressed a caspase-resistant ICADL2T/CAD  module in DT40 cells 
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lacking endogenous CAD and ICAD. ICAD-L 2TEV  is competent as a folding chaperone 
for CAD, and active nuclease was released following its cleavage with exogenous TEV, 
providing the first example of caspase-independent CAD activation and confirming that 
ICAD cleavage is sufficient to activate CAD. B23 and CIIA lack consensus cleavage 
sites for TEV, and DT40 cells expressing TEV appear to grow normally (AVA, 
unpublished). It therefore appears that DT40 cell-free extracts lack other proteins that 
can replace ICAD as inhibitors of CAD. 
These studies suggest a possible role for ICAD-S as a "buffer" of inhibitor to 
stop the sporadic loss or cleavage of ICAD-L from resulting in destruction of the 
genomic DNA. This is possible because ICAD-S acts as an inhibitor, but not a 
chaperone for CAD. ICAD-L cannot act as such a "buffer" since it also acts as a 
chaperone to promote the folding of active CAD. As a result, expression of higher 
levels of ICAD would simply raise the possibility of folding larger levels of active CAD. 
ICAD-L and ICAD-S are ubiquitously expressed during the mouse development (Zhang 
et al., 1999). The ratio of ICAD-S and ICAD-L varies in different tissues and organs 
(Chen et al., 2000; Kawane et al., 1999), and can be regulated at the level of alternative 
splicing (Li et al., 2005). Interestingly, in some tissues that are destined for long-term 
existence such as neurons, only ICAD-S is detected and not ICAD-L (Chen et al., 2000) 
(for contrasting results in human brain tissues see (Masuoka et al., 2001)). 
My study leads to a view of the ICAD/CAD module as a three-part system with 
ICAD-L acting both as activator and inhibitor of CAD, whilst ICAD-S is held in reserve 
as a "buffer" that prevents accidental activation of CAD. The humanized DT40 cell 
system described here should provide a useful asset for future studies of the role and 
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To investigate the role of CAD in cell death and the function of ICAD-S in vivo, 
ICAD and ICAD/CAD double knockouts were constructed in DT40 cells. The results of 
my PhD studies have led to the following conclusions and findings: 
ICAD and ICAD/CAD double knockouts are characterised by the absence of 
DNA fragmentation and stage II chromatin condensation. This data confirms the 
previous findings that CAD is absolutely required for DNA fragmentation in DT40 cells. 
ICAD is a mandatory chaperone for CAD, and therefore DNA fragmentation is absent 
even in ICAD knockouts with an intact CAD gene. In addition, CAD is required for the 
final stage II chromatin condensation that involves the formation of distinct apoptotic 
bodies. 
A method for the removal of loxP-neo-loxP and loxP-puro-loxP cassettes with 
transient transfection of Cre-recombinase was developed for use in DT40 cells. 
A method to remove drug-resistance cassettes that had been integrated into the genome 
flanked by mutant loxP sites was developed for DT40 cells. Marker gene removal after 
transient transfection with a vector encoding Cre-recombinase was highly efficient and 
did not require specific selection. 
Human ICAD and CAD proteins work as a module in the DT40 ICAD/CAD 
double knockout. Introduction of human ICAD-L and CAD proteins into the DT40 
(chicken) ICAD/CAD double knockout completely restored the DNA fragmentation and 
chromatin condensation phenotype. Therefore, these proteins can function as a module 
sufficient for DNA fragmentation and chromatin condensation during apoptosis. 
TEV protease technology for in vivo protein cleavage is not applicable in 
DT40 cells. Both TEV and mutant TEV protease proved to be unable to perform the 
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cleavage of hICAD12TE'  in DT40 cells. That was particularly surprising and 
disappointing, as substrate cleavage was efficiently performed in vitro using exogenous 
TEV protease. This excludes the possibility that the three-dimensional structure of the 
artificially engineered hICAD-L2T ' protein interfered with the cleavage. 
A novel technology for in vivo protein cleavage with PreScission protease has 
been developed in DT40 cells with potential application throughout vertebrate cells. The 
development of a new technology for site-specific protein cleavage with PreScission 
protease in vertebrate cells is a significant advancement of the tools available in cell 
biology for the study of protein function in vivo. This can be applied to identify the roles 
and mechanisms of action of a wide range of proteins if they are modified to have the 
PreScission protease cleavage site and then destroyed by protease cleavage. This method 
can be used to study protein function in cell lines through the depletion of the 
endogenous protein by genetic knockout or RNAi. 
Preliminary data suggests CAD activation may lead to cell death as a result of 
likely hICAD_LIPRE cleavage with PreScission protease. In the particular case of the 
application of PreScission protease technology to the model system to test the role of 
CAD in cell death, preliminary data from transient transfection experiments suggests 
that CAD activation may be sufficient to kill cells. A new model system with 
PreScission protease under tight regulation must be developed in vivo to confirm this 
data. 
Neither chicken nor human ICAD-S works as a chaperone for CAD. ICAD-S 
was not able to support the production of active CAD. Therefore, unlike ICAD-L, 
ICAD-S does not have chaperone function in vivo. 
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8. ICAD-S works as an inhi bitor for CAD in vivo and in vitro. ICAD-S is able to 
efficiently prevent CAD activation in vivo after ICAD-L cleavage. In addition, the 
cleavage of both ICAD-S and ICAD-L is required for CAD activation in vitro. 
Therefore, my study leads to a view of the ICAD/CAD module as a three-part system 
with ICAD-L acting both as activator and inhibitor of CAD, whilst ICAD-S is held in 
reserve as a 'buffer' that prevents accidental activation of CAD. 
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8. Future directions 
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The data and stable cell lines obtained during my PhD project suggest the following 
follow-up investigations: 
ICAD/CAD double knockouts provide a model system to study the initial 
stages of chromatin condensation in the absence of ICAD and CAD. Stage II DNA 
condensation is abolished in the ICAD/CAD double knockout. However, the stage I 
chromatin condensation is still present in the absence of CAD, and results in the 
formation of a necklace ring of small beads around the nuclear periphery. It would be 
interesting to identify the driving forces leading to the formation of this phenotype. As 
AIF is one of the factors contributing to DNA condensation, one possibility for studying 
the involvement of AIF in stage I condensation phenotype would be to deplete it with 
RNAi or genetic knockout in the ICAD/CAD double knockout and DT40 wild-type. 
This could provide a particular insight into the order and relative contribution of AIF 
and CAD action during apoptotic chromatin condensation. 
Study of ICAD-S:ICAD-L:CAD module function in the context of its 
localisation in cells. As both ICAD splice forms can inhibit CAD in vivo, it would be 
particularly interesting to determine the intracellular localisation of all the components 
before and after the induction of apoptosis, as well as their associations with each other. 
The stable cell line expressing CAD tagged with tandem purification tag could be used 
for this purpose. The tagged CAD protein could be used for the purification of 
associated proteins either from cytoplasmic or nuclear fractions. This would allow the 
identification of the particular ICAD splice forms associated with CAD in these 
compartments before and after the induction of apoptosis. Moreover, the system might 
allow the identification by mass spectrometry analysis of other proteins associated with 
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CAD or the ICAD:CAD complex. In addition, if ICAD-L and ICAD-S were also 
separately tagged, the subcellular localisation of all three components could be traced by 
fluorescence microscopy. 
3. New technology for site-specific protein cleavage with PreScission protease in 
vivo and inducing CAD activation in vivo. To further develop the new technology for 
site-specific protein cleavage with PreScission protease, it is necessary to establish an 
inducible model system with tight regulation for expression of the protease. PreScission 
protease is able to cleave its target when expressed, and therefore, expression system 
with tight regulation is required. One such system is the T-REx (Invitrogen), in which 
the expression of the desired protein product is prevented by the TetR repressor, 
positioned on the tet operator, thus preventing transcription. Expression is initiated when 
TetR is removed from the operator following binding of its inducer doxycycline. T-REx 
system contains two tet operators to accommodate two TetR for tighter regulation of 
PreScission protease regulation, until induced by Dox. The development of the 
PreScission protease inducible system would provide direct evidence that CAD 
activation after hICAD-L 2PRE  cleavage can cause cell death. 
If CAD activated in the absence of apoptosis can degrade the cellular DNA in 
vivo and kill the cell, this would suggest a possible approach to killing cancer cells 
through DNA cleavage. This could be done by discovering small molecular compounds 
that disrupt interactions between CAD and ICAD. Subsequent studies would address the 
possibilities of specifically targeting such compounds to cancer cells. Compounds 
capable of acting in such a way could then be used as anticancer drugs. Because CAD is 
situated at the end of the apoptotic signalling pathway, if it could be directly activated to 
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